<SEC-DOCUMENT>0001728117-23-000094.txt : 20230720
<SEC-HEADER>0001728117-23-000094.hdr.sgml : 20230720
<ACCEPTANCE-DATETIME>20230720160104
ACCESSION NUMBER:		0001728117-23-000094
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230719
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230720
DATE AS OF CHANGE:		20230720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gossamer Bio, Inc.
		CENTRAL INDEX KEY:			0001728117
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				475461709
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38796
		FILM NUMBER:		231099719

	BUSINESS ADDRESS:	
		STREET 1:		3013 SCIENCE PARK
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 922-0718

	MAIL ADDRESS:	
		STREET 1:		3013 SCIENCE PARK
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>goss-20230719.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:91a53403-3a34-43fc-84d5-df82498874be,g:c7abaad3-4801-48e8-9286-81ab07d36851,d:8955f600b1114eb4827da8d574ba95b2--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>goss-20230719</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001728117</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="goss-20230719.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-19</xbrli:startDate><xbrli:endDate>2023-07-19</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8955f600b1114eb4827da8d574ba95b2_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:27.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.782%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:27.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.782%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">July 19, 2023</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:27.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.782%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">GOSSAMER BIO, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:27.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.782%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38796</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">47-5461709</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">3013 Science Park Road</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">92121</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">684-1300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:27.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.782%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:36.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">GOSS</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.01 Entry into a Material Definitive Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2023, Gossamer Bio, Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with the purchasers named therein, including certain directors and executive officers of the Company (the &#8220;Purchasers&#8221;), for the private placement (the &#8220;Private Placement&#8221;) of 129,869,440 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), and accompanying warrants (the &#8220;Warrants&#8221; and together with the Shares, the &#8220;Securities&#8221;) to purchase up to 32,467,360 shares of Common Stock at a combined price of $1.63125 per Share and accompanying Warrant, or with respect to any Purchaser that is an officer, director, employee or consultant of the Company $1.85125 per Share and accompanying Warrant (collectively, the &#8220;Private Placement&#8221;). The aggregate gross proceeds for the Private Placement are expected to be approximately $212.1 million, before deducting placement agent fees and offering expenses, and assuming no exercise of the Warrants. The Private Placement is expected to close on July 24, 2023, subject to customary closing conditions. The Private Placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the &#8220;Minimum Price&#8221; and &#8220;market value&#8221; requirements (as defined in the Nasdaq rules). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to use the net proceeds from the Private Placement to fund the ongoing development and commercialization of seralutinib and for working capital and general corporate purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leerink Partners acted as lead placement agent for the private placement. H.C. Wainwright &amp; Co. acted as co-placement agent. Piper Sandler and Wedbush PacGrow acted as capital markets advisors to the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Warrant will have an exercise price per share of $2.04, will be immediately exercisable on the date of issuance and will expire five years from the closing of the Private Placement. Under the terms of the Warrants, the Company may not effect the exercise of any Warrant, and a holder will not be entitled to exercise any portion of any Warrant, which, upon giving effect to such exercise, would cause a holder (together with its affiliates) to own more than 4.99% (or, upon the election of the holder, prior to the issuance of the Warrant, 9.99%, 14.99% or 19.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 19.99% (or, upon election by the holder delivered to the Company prior to the issuance of the Warrant, 9.99%), provided that any increase in such percentage shall not be effective until 61 days after such notice is delivered to the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price and the number of shares of Common Stock issuable upon exercise of each Warrant will be subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock. The exercise price will not be adjusted below the par value of the Common Stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of certain fundamental transactions (as described in the Warrants), a holder of Warrants will be entitled to receive, upon exercise of the Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the Warrants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Purchase Agreement, the Company agreed to file a registration statement with the Securities and Exchange Commission (the &#8220;SEC&#8221;) within 30 days after the closing of the Private Placement (subject to certain exceptions) for purposes of registering the resale of the Shares and the shares of Common Stock issuable upon exercise of the Warrants, to use its reasonable best efforts to have such registration statement declared effective within the time period set forth in the Purchase Agreement, and to keep such registration statement effective for up to three years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Purchase Agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the Purchasers, including for liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and other obligations of the parties. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such Purchase Agreement and are made as of specific dates; are solely for the benefit of the parties (except as specifically set forth therein); may be subject to qualifications and limitations agreed upon by the parties in connection with negotiating the terms of the Purchase Agreement, instead of establishing matters as facts; and may be subject to standards of materiality and knowledge applicable to the contracting parties that differ from those applicable to the investors generally. Investors should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Private Placement is exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. The Purchasers </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">represented that they were accredited investors within the meaning of Rule 501(a) of Regulation D and were acquiring the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The securities were offered without any general solicitation by the Company or its representatives. The securities sold and issued in the Private Placement will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing description of the Purchase Agreement and Warrant does not purport to be complete and is qualified in its entirety by reference to the form of Securities Purchase Agreement and form of Warrant, which are filed as Exhibit 10.1 and 4.1, respectively, to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.02 Unregistered Sales of Equity Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosures set forth in Item 1.01 above are incorporated in this Item 3.02.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.01 Regulation FD Disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2023, the Company issued a press release announcing that it has entered into the Purchase Agreement. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information contained in this Item 7.01, including in Exhibit 99.1 hereto, is being &#8220;furnished&#8221; and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="goss-2023x07x19exx41.htm">Form of Warrant</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="goss-2023x0719xexx101.htm">Form of Securities Purchase Agreement</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="goss-2023x0719xexx991.htm">Press Release dated July 20, 2023</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statements in this report that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements regarding the completion of the Private Placement and the anticipated use of proceeds therefrom, and related to the anticipated filing of a registration statement to cover the resale of Shares and shares of Common Stock issuable upon exercise of the Warrants. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the Private Placement, as well as risks and uncertainties inherent in the Company&#8217;s business described in the Company&#8217;s prior press releases and the Company&#8217;s filings with the SEC, including under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2022 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof, except as required by law. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GOSSAMER BIO, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: July 20, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christian Waage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christian Waage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>goss-2023x07x19exx41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i092d401e3192458c8c46e2b72f16b595_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECURITIES ACT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). THE HOLDER MAY NOT OFFER, SELL, TRANSFER, ASSIGN, PLEDGE, HYPOTHECATE, OR OTHERWISE DISPOSE OF OR ENCUMBER SUCH SECURITIES EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAW, RESPECTIVELY, OR WITH AN EXEMPTION FROM SUCH REGISTRATION OR PROSPECTUS REQUIREMENT AND (II) IN COMPLIANCE WITH THAT CERTAIN SECURITIES PURCHASE AGREEMENT, DATED JULY 19, 2023, AMONG THE ISSUER AND THE PURCHASERS PARTY THERETO.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COMMON STOCK PURCHASE WARRANT </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GOSSAMER BIO, INC.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Warrant Shares&#58; _______&#160;&#160;&#160;&#160;Initial Exercise Date&#58; July 24, 2023</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) certifies that, for value received, _____________ or its assigns (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Initial Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and on or prior to 5&#58;00 p.m. (New York City time) on July 24, 2028 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) but not thereafter, to subscribe for and purchase from Gossamer Bio, Inc., a company incorporated under the laws of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), up to _________ shares (as subject to adjustment hereunder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Warrant Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:27pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Person directly or indirectly is controlled by, controlling or under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Bid Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, for any date, the price determined by the first of the following clauses that applies&#58; (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9&#58;30 a.m. (New York City time) to 4&#58;02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221; or any other similar orders or restrictions or the closure of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the United States Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Common Stock Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain Securities Purchase Agreement, dated as of July 19, 2023, by and among the Company and the investors signatory thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any weekday on which the Trading Market is open for trading. If the Common Stock is not listed or admitted for trading, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other governmental action to close.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Trading Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Nasdaq Global Select Market and any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question&#58; the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Transfer Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Computershare, Inc., the current transfer agent of the Company, located at 462 South 4th Street, Louisville, Kentucky 40202, and any successor transfer agent of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">VWAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, for any date, the price determined by the first of the following clauses that applies&#58; (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9&#58;30 a.m. (New York City time) to 4&#58;02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent Bid Price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Warrant Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means initially the Company, but upon ten (10) days&#8217; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#8217;s last address as shown on the Warrant Register. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means this Warrant and the other Common Stock purchase warrants issued by the Company pursuant to the Purchase Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:27pt">Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Exercise of Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed e-mail attachment of the Notice of Exercise in the form annexed hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Notice of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer unless the cashless exercise procedure specified in Section 2(c) below is applicable and specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The Holder and any permitted assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The exercise price per share of Common Stock under this Warrant shall be $2.04, subject to adjustment hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Cashless Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary set forth herein, if at any time there is no effective registration statement registering, or the prospectus contained therein is not available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing &#91;(A-B) (X)&#93; by (A), where&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A) &#61; as applicable&#58; (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Bloomberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B) &#61; the Exercise Price of this Warrant, as adjusted hereunder&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(X) &#61; the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rule or regulation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Mechanics of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Delivery of Warrant Shares Upon Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">DWAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144 promulgated under the Securities Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Rule 144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (assuming cashless exercise of the Warrant), and in each case, at the request of the Holder, in electronic book entry form to the account of the Holder or by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price (other than in the case of a cashless exercise) to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Warrant Share Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Standard Settlement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt;text-decoration:underline">Delivery of New Warrants Upon Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Rescission Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by providing the Company with written notice of rescission.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Buy-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Fractional Shares or Scrip</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round down to the nearest whole share.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Charges, Taxes and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt;text-decoration:underline">Closing of Books</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Holder&#8217;s Exercise Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise to the extent that immediately prior to or after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (including such group itself), any other Person who is a beneficial owner of Common Stock beneficially owned by the Holder or any of its Affiliates, and any other Persons whose beneficial ownership of the Common Stock would or could be aggregated with the Holders and the other foregoing Persons for purposes of Section 13(d) or Section 16 of the Exchange Act (such Persons, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Attribution Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable shall be the sole responsibility of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of the exercisability of this Warrant (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">confirm the accuracy of such determination and shall have no liability for exercises of this Warrant that are not in compliance with the Beneficial Ownership Limitation (other than to the extent that information on the number of outstanding shares of Common Stock of the Company is provided by the Company and relied upon by the Holder), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> any exercise of this Warrant and issuance of Common Stock in excess of the applicable Beneficial Ownership Limitation shall be null and void. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for purported exercises of this Warrant that are not in compliance with the Beneficial Ownership Limitation. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Beneficial Ownership Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be 4.99% (or, upon election by a Holder delivered to the Company prior to the issuance of any Warrants, 9.99%, 14.99% or 19.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Beneficial Ownership Limitation in no event exceeds 19.99% (or, upon election by a Holder delivered to the Company prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) of the Exchange Act or Rule 16a-1(a)(1) promulgated under the Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:27pt">Certain Adjustments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Stock Dividends and Splits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the Company, at any time while this Warrant is outstanding&#58; (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Subsequent Rights Offerings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Purchase Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Pro Rata Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) other than dividends, distributions or adjustments subject to Sections 3(a) and 3(b) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and other than a reclassification as to which Section 3(d) applies, then in each such case, at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the extent that the Holder&#8217;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Fundamental Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii) the Company effects any sale, transfer or disposition to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 3(a) above) (in any such case, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Fundamental Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Alternate Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous &#8220;cashless exercise&#8221; of this Warrant pursuant to Section 2 above or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (d) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Calculations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1&#47;100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Notice to Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Adjustment to Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt;text-decoration:underline">Notice to Allow Exercise by Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission on a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:27pt">Transfer of Warrant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Holder may transfer or assign this Warrant, provided that such transfer must be effected in compliance with applicable United States federal and states securities laws and the terms and conditions of this Warrant. Upon transfer, the Holder shall surrender this Warrant at the principal office of the Company or its designated agent, and provide a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">New Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Warrant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Warrant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Transfer Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered pursuant to an effective registration statement under the Securities Act or eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, will have restrictions upon resale imposed by state and federal securities laws and such Warrant Shares will be imprinted with the following legend&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:28.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;). THE HOLDER MAY NOT OFFER, SELL, TRANSFER, ASSIGN, PLEDGE, HYPOTHECATE, OR OTHERWISE DISPOSE OF OR ENCUMBER SUCH SECURITIES EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR PROSPECTUS UNDER THE SECURITIES ACT AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAW, RESPECTIVELY, OR WITH AN EXEMPTION FROM SUCH REGISTRATION OR PROSPECTUS REQUIREMENT AND (II) IN COMPLIANCE WITH THAT CERTAIN SECURITIES PURCHASE AGREEMENT, DATED JULY 19, 2023, AMONG THE ISSUER AND THE PURCHASERS PARTY THERETO.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Representation by Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:27pt">Miscellaneous.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">No Rights as Stockholder Until Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Loss, Theft, Destruction or Mutilation of Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Saturdays, Sundays, Holidays, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Authorized Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The failure of the Company to reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock a sufficient number of shares of Common Stock to enable it to issue Warrant Shares upon exercise of this Warrant as herein provided is referred to herein as an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Authorized Share Failure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221; The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. In furtherance of the Company&#8217;s obligations set forth in this Section 8, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than ninety (90) days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock. In connection with such meeting, the Company shall provide each stockholder with a proxy statement and shall use its reasonable best efforts to solicit its stockholders&#8217; approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal. Notwithstanding the foregoing, if at any such time of an Authorized Share Failure, the Company is able to obtain the written consent of a majority of the shares of its issued and outstanding shares of Common Stock to approve the increase in the number of authorized shares of Common Stock, the Company may satisfy this obligation by obtaining such consent and submitting for filing with the Commission an Information Statement on Schedule 14C.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In connection with any action which results in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of that certain Securities Purchase Agreement, dated July 19, 2023, among the Company and the purchasers party thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Nonwaiver and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, or via e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at Gossamer Bio, Inc., 3013 Science Park Road, San Diego, California 92121, Attention&#58; General Counsel, e-mail address&#58; jboerneke&#64;gossamerbio.com, or such other e-mail address or addresses as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5&#58;30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5&#58;30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Severabilit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">y. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><div id="i092d401e3192458c8c46e2b72f16b595_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GOSSAMER BIO, INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:233.9pt;text-indent:-17.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47;Faheem Hasnain&#160;&#160;&#160;&#160;</font></div><div style="padding-left:233.9pt;text-indent:-17.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Faheem Hasnain</font></div><div style="padding-left:233.9pt;text-indent:-17.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58; President and Chief Executive Officer</font></div><div style="padding-left:233.9pt;text-indent:-17.9pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Common Warrant&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTICE OF EXERCISE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TO&#58;&#160;&#160;&#160;&#160;GOSSAMER BIO, INC.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The undersigned hereby elects to purchase _________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Payment shall take the form of (check applicable box)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;in lawful money of the United States&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The time of day this Notice of Exercise is being executed is&#58; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Provided that the Warrant Shares are registered for resale on an effective registration statement or are eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Warrant Shares shall be delivered to the following DWAC Account Number&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;SIGNATURE OF HOLDER&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of Investing Entity&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Signature of Authorized Signatory of Investing Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of Authorized Signatory&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title of Authorized Signatory&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ASSIGNMENT FORM</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to __________, a&#91;&#47;n&#93; &#91;Affiliate&#93; &#91;successor&#93; of the Holder.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(Please Print) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(Please Print)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Phone Number&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email Address&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58; _______________________ ____, _______</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Holder&#8217;s Signature&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Holder&#8217;s Address&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>goss-2023x0719xexx101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5c2a5795721c4b79a1bbda1f19d78c53_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GOSSAMER BIO, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECURITIES PURCHASE AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">This Securities Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is made as of July 19, 2023 (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), by and among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gossamer Bio, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Purchasers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Purchasers desire to purchase, severally and not jointly, and the Company has agreed to sell, (i) shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and (ii) warrants, in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, to purchase shares of Common Stock equal to 25% of the Shares purchased by a Purchaser (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (the shares of Common Stock issuable upon the exercise of the Warrants, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Warrant Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Shares, Warrants and Warrant Shares are collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in connection with the issuance and sale of the Securities to the Purchasers on the terms and subject to the conditions set forth in this Agreement, the Company has entered into engagement letters (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Engagement Letters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), with each of Leerink Partners LLC, Piper Sandler &#38; Co. and H.C. Wainwright &#38; Co., LLC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Placement Agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Purchasers hereby agree, severally and not jointly, as follows&#58;</font></div><div style="text-indent:24.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;AUTHORIZATION OF SALE OF SECURITIES.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company has authorized the sale and issuance of the Securities to the Purchasers on the terms and subject to the conditions set forth in this Agreement.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 2.&#160;&#160;&#160;&#160;AGREEMENT TO SELL AND PURCHASE THE SECURITIES.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At the Closing, the Company will issue, sell and deliver to each Purchaser, and such Purchaser will purchase, severally and not jointly, from the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Purchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), that number of Shares and Warrants set forth opposite such Purchaser&#8217;s name on&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;hereto, at a price per Share, for the aggregate purchase price set forth thereon (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. For purposes of this Agreement, the following terms shall have the following meanings&#58;</font></div><div style="text-align:justify;text-indent:48.95pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, any Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Common Stock Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean any securities of the Company that would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Disclosure Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (i) if this Agreement is signed on a day that is not a Trading Day or after 9&#58;00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9&#58;01 a.m. (New York City time) on the Trading Day immediately following the date hereof, and (ii) if this Agreement is signed between midnight (New York City time) and 9&#58;00 a.m. (New York City time) on any Trading Day, no later than 9&#58;01 a.m. (New York City time) on the date hereof.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Exempt Issuance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the issuance of (a) shares of Common Stock, restricted stock units, options or other stock awards to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) the issuance and sale of the Securities to be issued hereunder and securities upon the exercise or exchange of or conversion of any Securities issued hereunder and&#47;or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c) securities issued pursuant to any licensing, collaboration, acquisition or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.07pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Knowledge of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to the Company, the knowledge, following due inquiry, of any of Faheem Hasnain, Bryan Giraudo, Richard Aranda, M.D., Christian Waage and Caryn Peterson. Such individuals will be deemed to have &#8220;knowledge&#8221; of a particular fact or other matter if such individual has or at any time had actual knowledge of such fact or other matter or if, in the absence of such actual knowledge, such person reasonably should have known such fact or other matter based on their role in the Company.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means United States generally accepted accounting principles.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Governmental Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any national, federal, state, county, municipal, local or foreign government, or other political subdivision thereof or any other governmental, administrative, judicial, arbitral, legislative, executive, regulatory or self-regulatory authority (including the Trading Market), instrumentality, agency, commission or body and any entity exercising executive, legislative, judicial, regulatory, taxing or administrative functions of or pertaining to government.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any federal, state, local or foreign law (including common law), statute, code, ordinance, rule, regulation, order, judgment, writ, stipulation, award, injunction, decree, arbitration award or finding or any other legally enforceable requirement.</font></div><div style="margin-bottom:12pt;padding-left:72.2pt;text-align:justify;text-indent:-23.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any change, event, development, condition, occurrence or effect that, individually or in the aggregate with all other changes, events, developments, conditions, occurrences or effects (a)&#160;is, or could reasonably be expected to be, materially adverse to the business, financial condition, prospects, assets, liabilities or results of operations of the Company and its subsidiaries considered as one enterprise, or (b)&#160;materially impairs the ability of the Company to comply, or prevents the Company from complying, with its material obligations with respect to the Closing or would </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">reasonably be expected to do so, or (c) is, or could reasonably be expected to be, materially adverse to the validity of the Securities purchased hereunder or the legal authority of the Company to comply in all material respects with the terms of this Agreement&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that none of the following will be deemed in themselves, either alone or in combination, to constitute, and that none of the following will be taken into account in determining whether there has been or will be, a Material Adverse Effect under subclause (a)&#160;of this definition&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">i.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">any change generally affecting the economy, financial markets or political, economic or regulatory conditions in the United States or any other geographic region in which the Company conducts business, if the Company is not disproportionately affected thereby&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">ii.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">general financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, if the Company is not disproportionately affected thereby&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">iii.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">any change that generally affects industries in which the Company conducts business, if the Company is not disproportionately affected thereby&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">iv.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">changes in Laws after the date hereof, if the Company is not disproportionately affected thereby&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">v.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">changes in GAAP after the date of this Agreement, if the Company is not disproportionately affected thereby&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">vi.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any change arising in connection with earthquakes, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage or terrorism or military actions&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">provided, that the underlying cause of any change described in the foregoing clauses (i) through (vi) may be deemed to constitute, or be taken into account in determining</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">whether there has been or will be, a Material Adverse Effect under subclause (a) of this definition, except to the extent any such change would otherwise be excepted from this definition in accordance with the foregoing.</font></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Per Share Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; equals $1.63125, or solely with respect to any Purchaser that is an officer, director, employee or consultant of the Company $1.85125, in each case subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement and prior to the Closing.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any individual or entity the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting stock or similar </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K promulgated under the Securities Act (as defined below).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a day on which the Trading Market is open for trading.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-23.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.07pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Trading Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Nasdaq Global Select Market.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 3.&#160;&#160;&#160;&#160;CLOSING, CLOSING CONDITIONS AND CLOSING DELIVERIES.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The closing of the purchase and sale of the Securities pursuant to this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall occur no later than 1&#58;00&#160;p.m., Pacific time, on July 24, 2023, subject to the satisfaction or waiver of all of the conditions set forth in&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;and the delivery of all of the closing deliveries set forth in&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;(such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), at the offices of Latham &#38; Watkins LLP, 12670 High Bluff Drive, San Diego, CA, 92130, or at such other time and place as may be agreed to by the Company and the Purchasers. </font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Closing Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mutual Closing Condition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. There shall have been no Law enacted, entered, promulgated, enforced or deemed applicable by any Governmental Entity of competent jurisdiction that is in effect and makes illegal or otherwise prohibits or materially delays the consummation of the Closing. If the Closing has not occurred for any reason on or prior to three days after the Closing Date, the Company shall promptly (but not later than one Business Day thereafter) return the Purchase Amount to each Purchaser by wire transfer of United States dollars in immediately available funds to the account specified by such Purchaser, and any book entries for the Securities (or, in the case of the Warrants, certificates) shall be deemed canceled&#59; provided that, unless this Agreement has been terminated pursuant to Section 10.14 hereof, such return of funds shall not terminate this Agreement or relieve such Purchaser of its obligations to purchase, or of the Company of its obligations to issue and sell, the Securities at the Closing.</font></div><div style="text-align:justify;text-indent:48.95pt"><font><br></font></div><div style="text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Conditions to Purchaser&#8217;s Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Purchaser&#8217;s obligation to purchase the Securities at the Closing is subject to the fulfillment, on or before the Closing, of each of the following conditions, unless waived&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">i.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company&#8217;s representations and warranties in&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;shall be true and correct in all material respects at the date of the Closing (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects), with the same force and effect as if they had been made on and as of said date, other than the representations and warranties set forth in Sections 4.1, 4.2, 4.3, 4.5, 4.8, 4.9, and 4.14 which shall be true and correct in all respects as if they had been made on and as of said date.</font></div></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">ii.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company shall have performed and complied with in all material respects all agreements and conditions herein required to be performed or complied with by the Company on or before the Closing, or any breach or failure to do so has been cured.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">iii.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">There shall have been no Material Adverse Effect with respect to the Company since the date hereof.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">iv.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">From the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or the Trading Market, nor shall suspension have been threatened either (A) in writing by the Commission or the Trading Market or (B) by falling below the minimum maintenance requirements of the Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on the Trading Market, nor shall a banking moratorium have been declared by the United States, New York State or California authorities.</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">v.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company shall have filed with the Trading Market a Listing of Additional Shares</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">notification form for the listing of the Shares and the Warrant Shares. No objection shall have been raised by the Trading Market with respect to the consummation of the transactions contemplated by this Agreement.</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">vi.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company shall have delivered the closing deliverables set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to the Purchasers.</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">vii.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of the purchase and sale of the Securities and the consummation of the other transactions contemplated by this Agreement, including the waiver of any applicable registration rights that could affect the rights of the Purchasers hereunder, all of which shall be in full force and effect.</font></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Conditions to the Company&#8217;s Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company&#8217;s obligation to issue and sell the Securities at the Closing to a Purchaser is subject to the fulfillment, on or before the Closing, of each of the following conditions, unless waived&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">i.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Such Purchaser&#8217;s representations and warranties in&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;shall be true and correct in all material respects at the date of the Closing, with the same force and effect as if they had been made on and as of said date,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date.</font></div></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">ii.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Such Purchaser shall have performed and complied with in all material respects all agreements and conditions herein required to be performed or complied with by it on or before the Closing, or any breach or failure to do so has been cured.</font></div></td></tr></table></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Closing Deliveries.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of the Purchase Price at Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At the Closing, each Purchaser shall deliver, or cause to be delivered, to the Company, an amount equal to such Purchaser&#8217;s aggregate Purchase Price as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto by wire transfer of immediately available funds to the Company&#8217;s </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">account pursuant to wire instructions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Purchaser&#8217;s obligations to pay the Purchase Price shall be several and not joint.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issuance of the Shares at the Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At the Closing, the Company shall issue, or cause the Company&#8217;s transfer agent to issue, to each Purchaser in global form through a book-entry account maintained by the Company&#8217;s transfer agent the number of Shares purchased by such Purchaser, as set forth in&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;hereto, at the Closing against payment by such Purchaser of the Purchase Price (including providing a copy of the irrevocable instructions delivered by the Company to the Company&#8217;s transfer agent instructing the transfer agent to issue the Shares to the Purchasers by crediting the Shares to the respective accounts of the Purchasers on the transfer agent&#8217;s book-entry system on the Closing Date and confirmation from the transfer agent that such Shares were so issued on the date thereof). Such Shares shall be appropriately legended as set forth in&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;herein.</font></div><div style="text-align:justify;text-indent:48.95pt"><font><br></font></div><div style="text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issuance of the Warrants at the Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At the Closing, the Company will deliver or cause to be delivered to each Purchaser a Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 25% of the Shares purchased  by such Purchaser and set forth opposite such Purchaser&#8217;s name on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto, with an exercise price equal to $2.04 per share, subject to adjustment therein, a PDF copy of which shall be provided to the Purchaser on the Closing Date, with original Warrant to be delivered to Purchaser within five (5) Business Days of Closing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Secretary&#8217;s Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At the Closing, the Purchasers shall have received a certificate signed by the Secretary of the Company, certifying the resolutions of the Board of Directors of the Company or a duly authorized committee thereof approving this Agreement and all of the transactions contemplated hereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At the Closing, the Purchasers shall have received a certificate signed by the President and Chief Executive Officer of the Company certifying to the fulfillment of the conditions set forth in&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;3.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Opinion. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">At the Closing, the Purchasers shall have received an opinion of Latham &#38; Watkins LLP, counsel for the Company, dated as of the Closing Date, in a form reasonably satisfactory to the Purchasers.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lock-up Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At the Closing, the Purchasers shall have received executed lock-up agreements, dated as of the date hereof, by and among the Company and the directors and executive officers of the Company, all of whom are listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto, in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">D&#38;O Lock-up</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 4.&#160;&#160;&#160;&#160;REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as disclosed in the SEC Documents (as defined below) prior to the date of this Agreement and only as and to the extent disclosed therein, the Company hereby represents, warrants and covenants to the Purchasers and Placement Agents as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Organization and Standing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company has been duly incorporated or organized and is validly existing and in good standing under the laws of Delaware or other jurisdiction of incorporation or organization, has full corporate or other power and authority necessary to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and in good standing in all jurisdictions in which the character of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not reasonably be expected to have a Material Adverse Effect. The Company owns, directly or through subsidiaries, all of the issued outstanding equity securities of each of its subsidiaries. Each of the Company&#8217;s subsidiaries has been duly incorporated or organized and is validly existing and in good standing under the laws of its jurisdiction of incorporation or organization, has full corporate or other power and authority necessary to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and in good standing in all jurisdictions in which </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the character of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Corporate Power&#59; Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company has all requisite corporate power and authority, and the Company and its Board of Directors have taken all requisite corporate action, to authorize, execute and deliver this Agreement and the Warrants, to consummate the transactions contemplated herein and therein, including to sell, issue and deliver the Securities to the Purchasers, and to carry out and perform all of the Company&#8217;s obligations hereunder and thereunder. This Agreement has been duly authorized, executed and delivered by the Company and constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except (i)&#160;as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#8217; rights generally and (ii)&#160;as limited by equitable principles generally, including any specific performance.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issuance and Delivery of the Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Shares have been duly authorized and, when issued and paid for in compliance with the provisions of this Agreement, will be validly issued, fully paid and nonassessable. The Warrants have been duly authorized by the Company and when executed and delivered by the Company will be valid and binding agreements of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles.  The issuance and delivery of the Shares or Warrants is not subject to preemptive,&#160;co-sale,&#160;right of first refusal or any other similar rights of the stockholders of the Company or any other Person or any liens or encumbrances, other than encumbrances under applicable securities laws. The Warrant Shares have been duly authorized and reserved for issuance and, when issued and delivered upon valid exercise of the Warrants in accordance therewith, will be validly issued, fully paid and nonassessable, and not subject to preemptive,&#160;co-sale,&#160;right of first refusal or any other similar rights of the stockholders of the Company or any other Person or any liens or encumbrances, other than encumbrances under applicable securities laws or the Warrants. Assuming the accuracy of the representations made by the Purchasers in&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the offer and issuance by the Company of the Securities is exempt from registration under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SEC Documents&#59; Financial Statements&#59; Independent Accountants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company is not an &#8220;ineligible issuer&#8221; (as defined in Rule 405 promulgated under the Securities Act). The Company is subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and has filed or furnish or will file or furnish in a timely manner all reports, schedules, forms, statements and other documents that the Company was or is required to file with the Commission under either the Securities Act or the Exchange Act, since becoming subject to the requirements of the Exchange Act (the foregoing documents (together with any documents filed by the Company under the Securities Act or Exchange Act, whether or not required), and in each case including all exhibits and schedules thereto and documents incorporated by reference therein and including all registration statements and prospectuses filed with the Commission, but excluding any information for which the Company has received confidential treatment from the Commission, being collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">SEC Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), all of which are available on the Commission&#8217;s EDGAR system. As of their respective filing or furnishing dates (or, if amended prior to the date of this Agreement, when amended), all SEC Documents (including any audited or unaudited financial statements and any notes thereto or schedules included therein) complied in all material respects with the requirements of the Securities Act or the Exchange Act, as the case may be, and the rules and regulations of the Commission promulgated thereunder. None of the SEC Documents as of their respective filing or furnishing dates contained any untrue statement of material fact or omitted to state a material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading. There are no material outstanding or unresolved comments in comment letters from the staff of the Division of Corporation Finance of the Commission with respect to any SEC Documents. The Company meets the requirements for the use of Form S-3 under the Securities Act. The financial statements (including the notes thereto) of the Company set forth in the SEC Documents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) comply in all material respects with applicable accounting requirements and with the </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">published rules and regulations of the Commission with respect thereto. The Financial Statements have been prepared in accordance with GAAP consistently applied during the periods involved and fairly present the financial position of the Company at the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal, immaterial recurring adjustments). Except as set forth in the Financial Statements filed prior to the date hereof, the Company has not incurred any liabilities, contingent or otherwise, except those incurred in the ordinary course of business, consistent (as to amount and nature) with past practices since the date of such Financial Statements, none of which, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect. The accountants who certified the Financial Statements are independent public accountants as required by the Securities Act and the Exchange Act and the regulations thereunder and the Public Company Accounting Oversight Board.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Capitalization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The authorized capital stock of the Company consists of 700,000,000 shares of Common Stock and 70,000,000 shares of preferred stock. As set forth in the SEC Documents as of the date set forth therein, all of the Company&#8217;s outstanding shares of capital stock have been duly authorized and validly issued and are fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and were not issued in violation of or subject to any preemptive right or other rights to subscribe for or purchase securities. Except as disclosed in the SEC Documents, there are no existing options, warrants, calls, subscriptions or other rights, agreements, arrangements or commitments of any character, relating to the issued or unissued capital stock of the Company, obligating the Company to issue, transfer, sell, redeem, purchase, repurchase or otherwise acquire or cause to be issued, transferred, sold, redeemed, purchased, repurchased or otherwise acquired any capital stock or voting debt of, or other equity interest in, the Company or securities or rights convertible into or exchangeable for such shares or equity interests or obligations of the Company to grant, extend or enter into any such option, warrant, call, subscription or other right, agreement, arrangement or commitment.&#160;Neither the execution of this Agreement nor the issuance of Common Stock or other securities pursuant to any provision of this Agreement or the Warrants will give rise to any preemptive rights or rights of first refusal on behalf of any Person or result in the triggering of any anti-dilution or other similar rights (including a rights distribution under any &#8220;poison pill&#8221; plan or similar arrangement). Other than the Common Stock, there are no other shares of any other class or series of capital stock of the Company issued or outstanding. The Company&#8217;s Certificate of Incorporation, as amended and as in effect on the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and the Company&#8217;s Bylaws, as amended and as in effect on the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), are included in the SEC Documents, and the Company shall not amend or otherwise modify the Certificate of Incorporation or Bylaws prior to the Closing. Except as disclosed in the SEC Documents, there are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of any kind among the Company and any of the security holders of the Company relating to the securities of the Company held by them.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. There are no legal, governmental or regulatory actions, suits, investigations, charges, claims, complaints, audits, inquiries or other proceedings pending or, to the Knowledge of the Company, threatened against the Company or any of its subsidiaries, before or by any court, regulatory body or administrative agency or any other governmental agency or body, domestic or foreign, which actions, suits or proceedings, individually or in the aggregate, could reasonably be expected to (a)&#160;challenge this Agreement or prohibit or delay the transactions contemplated herein or (b)&#160;have a Material Adverse Effect. Neither the Company nor any of its subsidiaries, is a party to or subject to the provisions of any injunction, judgment, decree or order of any court, regulatory body, administrative agency or other governmental agency or body that might have a Material Adverse Effect. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company under the Securities Act or the Exchange Act.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state, or local governmental authority or the Trading Market on the part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement except for the filing of a Form D with the Commission under the Securities Act and compliance with the securities and blue sky laws in the states and other jurisdictions in which shares of Common Stock are offered or sold, which compliance will be effected by the Company in accordance with such laws.</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No Default or Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither the Company nor any of its subsidiaries, is in violation or default under its organizational documents. Neither the execution, delivery or performance of this Agreement or the Warrants by the Company nor the consummation of any of the transactions contemplated hereby or thereby (including the issuance, sale and delivery by the Company of the Securities) will&#58; (i)&#160;give rise to a right to terminate or accelerate the due date of any payment due under, or conflict with or result in the breach of any term or provision of, or constitute a default (or an event which with notice or lapse of time or both would constitute a default) under, or require any consent or waiver under, or result in the execution or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or any subsidiary pursuant to the terms of, any indenture, mortgage, deed of trust or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which either or them or any of their respective properties or businesses are bound, or any franchise, license, permit, judgment, decree, order, statute, rule or regulation (including federal and state securities laws and regulations) and the rules and regulations, assuming the correctness of the representations and warranties made by the Purchasers herein, of any self-regulatory organization to which the Company or any of its subsidiaries or their securities are subject) applicable to the Company, or (ii)&#160;violate or conflict with any provision of the Certificate of Incorporation or the Bylaws, except in the case of clause (i)&#160;as would not reasonably be expected to cause, either individually or in the aggregate, a Material Adverse Effect, and except for such consents or waivers which have already been obtained and are in full force and effect.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No Material Adverse Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Since December&#160;31, 2022, except as specifically disclosed in the SEC Documents filed or furnished at least one Trading Day prior to the Effective Date, (a) the Company has conducted its business only in the ordinary course and (b) there have been no events, occurrences or developments that have had or would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. Except for the transactions contemplated by this Agreement, no event, liability or development has occurred or exists with respect to the Company or any of its subsidiaries or their respective businesses, properties, operations or financial conditions that would be required to be disclosed by the Company under applicable securities laws at the Effective Date that has not been publicly disclosed at least one Trading Day prior to the Effective Date. Since March 31, 2023, except as specifically disclosed in the SEC Documents filed or furnished prior to the Effective Date, there has not been&#58; (a) any material damage, destruction or loss, whether or not covered by insurance, to any assets or properties of the Company or any of its subsidiaries&#59; (b) any change or amendment to any of the Company&#8217;s or any of its subsidiaries&#8217; organizational documents or termination or material amendment to any contract or arrangement by which the Company is bound or to which any of its assets or properties are subject or that the Company is or was required to file with the Commission pursuant to Item 601(b)(10) of Regulation S-K&#59; (c) any material labor difficulties or, to the Knowledge of the Company, labor union organizing activities with respect to employees of the Company&#59; or (d) the loss of the services of any executive officer (as defined in Rule 405 under the Securities Act) of the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No General Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D promulgated under the Securities Act) in connection with the offer or sale of the Securities.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No Integrated Offering.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration the offer or sale of any of the Securities under the Securities Act or cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of the Securities Act or any applicable stockholder approval provisions, including under the rules and regulations of the Trading Market.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sarbanes-Oxley Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company is in material compliance with the requirements of the Sarbanes-Oxley Act of 2002 that are effective and applicable to the Company as of the date hereof, and the rules and regulations promulgated by the Commission thereunder that are effective and applicable to the Company as of the date hereof.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Intellectual Property.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To the Knowledge of the Company, the Company and its subsidiaries own, possess, license or have rights to use, on terms that the Company believes to be reasonable, all </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">patents, patent applications, trademarks, trademark applications, service marks, trade names, copyrights, licenses, trade secrets,&#160;know-how&#160;and other similar rights that are necessary or material for use in connection with the businesses of the Company and its subsidiaries as described in the SEC Documents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).&#160;Neither the Company nor any of its subsidiaries has received a written notice that the Intellectual Property Rights used by the Company or any subsidiary violates or infringes upon the rights of any Person.&#160;To the Knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its subsidiaries have taken reasonable security measures to protect the secrecy and confidentiality of the Intellectual Property Rights (excluding any patents or patent applications that have or will become public), except where the failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. To the Knowledge of the Company, all material licenses or other material agreements under which the Company is granted rights to intellectual property are in full force and effect and there is no material default by any other party thereto.  The Company has no reason to believe that the licensors under such licenses and other agreements do not have and did not have all requisite power and authority to grant the rights to the Intellectual Property purported to be granted thereby.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;The Company understands and confirms that the Purchasers will rely on the representations, warranties and covenants set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> in effecting the transactions contemplated by this Agreement. All due diligence materials regarding the Company and its business and the transactions contemplated hereby (including the information referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof), furnished by or on behalf of the Company to the Purchasers upon their request are, when taken together with the SEC Documents, true and correct in all material respects and do not contain any untrue statement of material fact or omit to state a material fact necessary in order to make the statements made therein, in light of the circumstances in which they were made, not misleading. The Company understands and agrees that each Purchaser, in making its decision to enter into this Agreement and purchase its Securities, will rely on such due diligence materials and SEC Documents. Except with respect to the material terms and conditions of the transactions contemplated by this Agreement, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or would reasonably be expected to constitute material, non-public information that will not otherwise be disclosed in the Disclosure Document (as defined below).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Contracts.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Each indenture, contract, lease, mortgage, deed of trust, note agreement, loan or other agreement or instrument of a character that is required to be described or summarized in the SEC Documents or to be filed as an exhibit to the SEC Documents under the Exchange Act and the rules and regulations promulgated thereunder (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Material Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is so described, summarized or filed.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The Material Contracts to which the Company or any of its subsidiaries is a party have been duly and validly authorized, executed and delivered by the Company or such subsidiary and constitute the legal, valid and binding agreements of the Company or such subsidiary, enforceable by and against the Company and its subsidiaries in accordance with their respective terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or other similar laws relating to enforcement of creditors&#8217; rights generally, and general equitable principles relating to the availability of remedies, except as rights to indemnity or contribution may be limited by federal or state securities laws. Neither the Company nor any of its subsidiaries nor, to the Knowledge of the Company, any third party has violated any provision of, or failed to perform any obligation required under the provisions of, any of the  Material Contracts. Neither the Company nor any of its subsidiaries nor, to the Knowledge of the Company, any third party is in breach or default, or has received written notice of breach or default, of any of the Material Contracts. To the Knowledge of the Company, no event has occurred that, with notice or lapse of time or both, would constitute such a breach or default pursuant to any Material Contract by the Company or any of its subsidiaries, or, to the Knowledge of the Company, any other party thereto, and, as of the date of this Agreement, neither the Company nor any of its subsidiaries has received written notice of the foregoing or from the counterparty to any Material Contract (or, to the Knowledge of the Company, any of such counterparty's Affiliates) regarding an intent to </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">terminate, cancel, or modify any Material Contract (whether as a result of a change of control or otherwise).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Properties and Assets.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;The Company and its subsidiaries have good and marketable title to all the properties and assets described as owned by them in the latest Financial Statements set forth in the SEC Documents, free and clear of all liens, mortgages, pledges, encumbrances or defects of any kind except (a)&#160;those, if any, reflected in such Financial Statements or (b)&#160;those that are not material in amount and do not adversely affect the use made and proposed to be made of such property by the Company or any subsidiary. The Company and its subsidiaries hold their respective leased properties under valid, subsisting and enforceable leases, except as would not reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries own or lease all such properties as are materially necessary to their respective operations as now conducted.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance and Regulatory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company and its subsidiaries are in compliance with all applicable Laws of the jurisdictions in which they are conducting their business, including all applicable local, state and federal environmental Laws (including Laws relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances), and all applicable Laws enforced by the United States Food and Drug Administration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), (including the Federal Food, Drug And Cosmetic Act, as amended, and the regulations promulgated thereunder) or any applicable laws enforced by equivalent Governmental Entities outside the United States, except where failures to be so in compliance, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. Any preclinical tests and studies or clinical trials conducted by, on behalf of, or sponsored by the Company or any of its subsidiaries (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Studies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), were and, if still pending, are being conducted in all material respects in accordance with all applicable laws and regulations and protocols governing the conduct of such Studies, the protocols, procedures and controls submitted to the FDA or any foreign governmental body exercising comparable authority (together with the FDA, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and any conditions of approval and policies imposed by any institutional review board, ethics review board or committee responsible for the oversight of such preclinical tests and studies and clinical trials. The descriptions of the Studies contained in the SEC Documents are accurate in all material respects&#59; to the Knowledge of the Company, there are no other preclinical studies and clinical trials, the results of which are inconsistent with or would call into question the results described in the SEC Documents in any material respect&#59; and neither the Company nor any of its subsidiaries has received any written notice or correspondence from the FDA or any other Regulatory Authority or institutional review board exercising comparable authority requiring or threatening the termination, suspension, or material adverse modification of Studies currently being conducted or proposed to be conducted by the Company and its subsidiaries, where such termination, suspension or modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">would reasonably be expected to have a Material Adverse Effect, and to the Knowledge of the Company, there are no reasonable ground for the same. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company and its subsidiaries have filed on a timely basis (giving effect to extensions) all required federal, state and foreign income, franchise and other tax returns and have timely paid or accrued all taxes shown as due thereon, including interest and penalties, and there is no tax deficiency that has been or might be asserted or threatened against it or them that could have a Material Adverse Effect. All tax liabilities accrued through the date hereof have been adequately provided for on the books of the Company. There are no liens for material taxes upon the assets of the Company or any of its subsidiaries other than for current taxes not yet due and payable or for taxes that are being contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP has been made in the Company's most recent financial statements included in the SEC Documents. The Company is classified as a Subchapter C corporation for U.S. federal tax purposes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Investment Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;The Company is not, and immediately after receipt of payment for the Securities will not be, an &#8220;investment company&#8221; or an &#8220;affiliated person&#8221; of, or &#8220;promoter&#8221; or &#8220;principal underwriter&#8221; for an investment company, within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission promulgated thereunder.</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insurance.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company maintains insurance underwritten by insurers of recognized financial responsibility, of the types and in the amounts that the Company reasonably believes is adequate for the businesses of the Company and its subsidiaries, including directors&#8217; and officers&#8217; liability insurance and insurance covering all real and personal property owned or leased by the Company or any of its subsidiaries against theft, damage, destruction, acts of vandalism and all other risks customarily insured against and against such risks which the Company believes it is prudent to insure against, with such deductibles as are customary for companies in the same or similar business, all of which insurance is in full force and effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Price of Common Stock.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;The Company has not taken, and will not take, and no Person acting on its behalf has taken or will take, directly or indirectly, any action designed to cause or result in, or that has constituted or that might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Permits, Etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;The Company and its subsidiaries have all franchises, licenses, permits, certificates and other authorizations from such federal, state or local government or governmental agency, department or body that are currently necessary for the operation of their respective businesses as currently conducted, including all such certificates, approvals, authorizations, exemptions, licenses and permits required by the FDA or any other comparable Governmental Entities, including other Regulatory Authorities (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), except where the failure to possess such Permits  would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any written notice requiring or threatening any revocation or modification of any such Permits, where such revocation or modification would reasonably be expected to have a Material Adverse Effect.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Internal Control over Financial Reporting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;The Company maintains internal control over financial reporting (as such term is defined in paragraph (f)&#160;of Rule&#160;13a-15&#160;under the Exchange Act) as required by Rule&#160;13a-15&#160;under the Exchange Act, including to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company maintains a system of internal accounting controls (a) designed to ensure that (i) material information relating to the Company, including its subsidiaries, is made known to the Company&#8217;s principal executive officer and principal financial officer by others within those entities and (ii) information required to be disclosed by the Company in reports that it files, furnishes or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified int he Commission&#8217;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated the Company&#8217;s management as appropriate to allow timely decisions regarding required disclosure and (b) sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect to any differences. The Company's certifying officers have evaluated the effectiveness of the Company's disclosure controls and procedures and the Company&#8217;s internal control over financial reporting (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">internal controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Evaluation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of such internal controls based on their evaluations as of the Evaluation Date. Since the end of the Company&#8217;s most recent audited fiscal year, there has been no material weakness in the design or operation of the Company&#8217;s internal control over financial reporting (whether or not remediated). The Company maintains and will continue to maintain a standard system of accounting established and administered in accordance with GAAP and the applicable requirements of the Exchange Act.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign Corrupt Practices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Neither the Company nor, to the Knowledge of the Company, any of its subsidiaries nor any director, officer, agent, employee or other Person acting on behalf of the Company or any of its subsidiaries, has, in the course of its actions for, or on behalf of, the Company or </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any subsidiary (a)&#160;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity&#59; (b)&#160;made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds&#59; (c)&#160;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act 2010 or any similar Law&#59; or (d)&#160;made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Employee Relations.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> No material labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company or any of its subsidiaries, exists or, to the Knowledge of the Company, is threatened or imminent. No executive officer of the Company (as defined in Rule 501(f) promulgated under the Securities Act) has notified the Company that such officer intends to leave the Company or otherwise terminate such officer&#8217;s employment with the Company. To the Knowledge of the Company, no executive officer of the Company is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement,&#160;non-competition&#160;agreement, or any other agreement or any restrictive covenant involving or otherwise affecting such executive officer&#8217;s relationship with the Company, and the continued employment of each such executive officer does not and will not subject the Company to any material liability with respect to any of the foregoing matters.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ERISA.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;The Company and its subsidiaries are in compliance in all material respects with all presently applicable provisions of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; no &#8220;reportable event&#8221; (as defined in ERISA) has occurred with respect to any &#8220;pension plan&#8221; (as defined in ERISA) for which the Company or any subsidiary would have any material liability&#59; neither the Company nor any of its subsidiaries has not incurred or expects to incur material liability under (a)&#160;Title IV of ERISA with respect to termination of, or withdrawal from, any &#8220;pension plan&#8221; or (b)&#160;Sections 412 or 4971 of the Internal Revenue Code of 1986, as amended, including the regulations and published interpretations thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and each &#8220;Pension Plan&#8221; for which the Company or any of its subsidiaries would have liability that is intended to be qualified under Section&#160;401(a)&#160;of the Code is so qualified in all material respects and to the Knowledge of the Company, nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.27&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Registration Rights and Other Stockholder Agreements.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No Person has any right to cause the Company to effect the registration under the Securities Act covering the transfer of any securities of the Company and there are no other stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s capital stock to which the Company is a party or, to the Knowledge of the Company, between or among any of the Company&#8217;s stockholders.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.28&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trading Market Compliance.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Trading Market under the symbol &#8220;GOSS&#8221;. The Company has not, in the previous twelve (12)&#160;months, received, nor is there any reasonable basis for, (i)&#160;written notice from the Trading Market that the Company is not in compliance with the listing or maintenance requirements of the Trading Market that would result in immediate delisting, (ii)&#160;any notification, Staff Delisting Determination, or Public Reprimand Letter (as such terms are defined in applicable listing rules of the Trading Market) that requires a public announcement by the Company of any noncompliance or deficiency with respect to such listing or maintenance requirements or (iii) the delisting of the Common Stock from the Trading Market. The Company is in compliance with all listing and maintenance requirements of the Trading Market on the date hereof.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.29&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No &#8220;Bad Actor&#8221; Disqualification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;No &#8220;bad actor&#8221; disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Disqualification Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is applicable to the Company or, to the Knowledge of the Company, any Company Covered Person (as defined below), except for a Disqualification Event to which Rule&#160;506(d)(2)(ii-iv)&#160;or (d)(3) is applicable. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company Covered Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to the Company as an &#8220;issuer&#8221; for purposes of Rule 506 promulgated under the Securities Act, any person listed in the first paragraph of Rule 506(d)(1).</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.30&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OFAC&#59; Sanctions.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">None of the Company, any of its subsidiaries or, to the Knowledge of the Company, any director, officer, agent, employee, Affiliate or representative of the Company or any of its subsidiaries is a Person that is, or is more than 50 percent owned in the aggregate by or acting on behalf of one or more Persons that are, currently the subject or target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, His Majesty&#8217;s Treasury, or other relevant sanctions authority (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions&#59; and the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business (i) with any Person, or in any country or territory, that, at the time of such funding, is a designated target of Sanctions, (ii) in or involving a country or territory which at the time of such funding is the subject of comprehensive country-wide or territory-wide Sanctions, or (iii) in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. The Company has not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.31&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Shell Company Status.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Company is not, and has never been, an issuer identified in Rule 144(i)(1).</font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.32&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance with Anti-Money Laundering Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental or regulatory agency (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Anti-Money Laundering Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and no action, suit or proceeding by or before any court or governmental or regulatory agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the Knowledge of the Company, threatened.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.33&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transactions with Affiliates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Except as disclosed in the SEC Documents, none of the officers or directors of the Company and, to the Company&#8217;s Knowledge, none of the employees of the Company is presently a party to any transaction with the Company (other than as holders of stock options or warrants, and for services as employees, officers and directors or as parties to this Agreement), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.34&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No Additional Agreements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Company has no other agreements or understandings (including side letters) with any Purchaser or any other Person to purchase Securities on terms more favorable to such Purchaser than as set forth herein.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PURCHASERS.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Purchaser, severally and not jointly, represents and warrants to and covenants with the Company and Placement Agents that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Risk.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Such Purchaser, taking into account the personnel and resources it can practically bring to bear on the purchase of the Securities contemplated hereby, is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments in securities </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">presenting an investment decision like that involved in the purchase of the Securities, including investments in securities issued by the Company, and has requested, received, reviewed and considered all information such Purchaser deems relevant (including the SEC Documents) in making an informed decision to purchase the Securities.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchase for Investment.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchaser is acquiring the Securities pursuant to this Agreement for its own account for investment only and with no present intention of distributing any of such Securities or any arrangement or understanding with any other Persons regarding the distribution of such Securities, except in compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Such Purchaser understands that the Securities are being offered and sold to it in reliance upon specific exemptions from the registration requirements of the Securities Act, the rules and regulations thereunder, and state securities laws and that the Company is relying upon the truth and accuracy of, and such Purchaser&#8217;s compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Securities. If any of the representations and warranties made by such Purchaser herein are no longer accurate in all material respects prior to Closing, such Purchaser shall promptly notify the Company. If such Purchaser is acquiring the Securities as a fiduciary or agent for one or more investor accounts, it represents that it has sole investment discretion with respect to each such account and it has full power to make the foregoing representations, acknowledgements and agreements on behalf of such account.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance with the Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Such Purchaser will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the securities purchased hereunder except in compliance with the Securities Act, applicable blue sky laws, and the rules and regulations promulgated thereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accredited Investor.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Such Purchaser is an &#8220;accredited investor&#8221; within the meaning of Rule&#160;501 of Regulation D promulgated under the Securities Act or a Qualified Institutional Buyer within the meaning of Rule 144A promulgated under the Securities Act.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Power and Authority.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Such Purchaser has all requisite corporate power, and has taken all requisite corporate action, to authorize, execute and deliver this Agreement and each of the other agreements and instruments contemplated herein to which the Purchaser is a party, to consummate the transactions contemplated herein and therein and to carry out and perform all of such Purchaser&#8217;s obligations hereunder and thereunder. Upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of such Purchaser, enforceable in accordance with its terms, except (i)&#160;as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#8217; rights generally and (ii)&#160;as limited by equitable principles generally, including any specific performance.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Broker Dealer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Such Purchaser is not a broker or dealer registered pursuant to Section&#160;15 of the Exchange Act.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sophisticated Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Such Purchaser acknowledges that it is a sophisticated investor engaged in the business of assessing and assuming investment risks with respect to securities, including securities such as the Shares, Warrants and Warrant Shares, and further acknowledges that the Company is entering into this Agreement in reliance on this acknowledgment. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Securities Transactions.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Such Purchaser has not, either directly or indirectly through an Affiliate, agent or representative of the Company, engaged in any transaction in the securities of the Company other than with respect to the transactions contemplated herein, since the time that the Purchaser was first contacted by the Company or any other Person regarding the transactions contemplated hereby until the date hereof, except as set forth in filings made with the Commission pursuant to the Exchange Act. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets, the representation set forth above shall only apply with respect to the portion of assets </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">managed by the portfolio manager that made the investment decision to purchase the Securities&#8217; covered by this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Independent Advice.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Such Purchaser understands that nothing in this Agreement or any other materials presented to such Purchaser by or on behalf of the Company in connection with the purchase and sale of the Securities constitutes legal, tax or investment advice. Such Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities. Each Purchaser acknowledges and agrees that the Placement Agents shall have no liability or obligation (including without limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by such Purchaser, the Company or any other person or entity), whether in contract, tort or otherwise, to the Purchaser, or to any person claiming through such Purchaser, in respect of the transactions contemplated hereby. Each Purchaser acknowledges and agrees that the Placement Agents shall have no liability or obligation on or with respect to the accuracy or completeness, as of any date, of any information set forth in, or any omission from, any valuation or other materials that may have been provided or made available to the Purchaser in connection with the transactions contemplated hereby. Each Purchaser is not relying upon, and has not relied upon, any statement, representation or warranty made by any person, including, without limitation, Leerink Partners LLC, Piper Sandler &#38; Co. and H.C. Wainwright &#38; Co., except for the statements, representations and warranties contained in this Agreement. Leerink Partners LLC, Piper Sandler &#38; Co. and H.C. Wainwright &#38; Co., LLC shall be a third-party beneficiary of, and shall be entitled to rely on, the representations and warranties described in this Section 5.10.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Legends.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Such Purchaser understands that, until such time as the Securities may be sold pursuant to an effective registration statement or Rule 144 under the Securities Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Rule 144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (or any other applicable exemption from the registration requirements under the Securities Act), any certificates representing the Securities, whether maintained in a book entry system or otherwise, will bear one or more legends in substantially the following form and substance&#58;</font></div><div style="margin-top:12pt;padding-left:58.5pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;THE OFFER AND SALE OF THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A TRANSACTION WHICH IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS, AND, IN THE CASE OF A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, THE HOLDER WILL NOTIFY ANY SUBSEQUENT PURCHASER OF THE SECURITIES EVIDENCED BY THIS CERTIFICATE FROM IT OF SUCH RESALE RESTRICTIONS.&#8221;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, any stock certificates, whether maintained in a book entry system or otherwise, representing the Securities may contain any legend required by the blue sky laws of any state to the extent such laws are applicable to the sale of such Securities hereunder. The Company shall promptly help facilitate the removal of such legend as soon as it is legally permitted to do so under Rule 144, or to facilitate any transfer of the Securities under Rule 144 that may be requested by Purchasers, but shall not be obligated to incur any material, noncustomary costs or expenses in taking such actions other than as set forth herein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company shall, at its sole expense, upon appropriate notice from any Purchaser stating that Registrable Securities have been sold pursuant to an effective Registration Statement, under Rule 144, or any other exemption from the registration requirements under the Securities Act, within two (2) Trading Days of such notice, cause its transfer agent to timely prepare and deliver certificates or book-entry shares </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">representing the Shares and Warrant Shares to be delivered to a transferee pursuant to such sale, which certificates or book-entry shares shall be free of any restrictive legends and in such denominations and registered in such names as such Purchaser may request. Further, the Company shall, at its sole expense, cause its legal counsel or other counsel satisfactory to the transfer agent&#58; (i) while the Registration Statement is effective, to issue to the transfer agent a &#8220;blanket&#8221; legal opinion to allow sales without restriction pursuant to the effective Registration Statement, and (ii) provide all other opinions as may reasonably be required by the transfer agent in connection with the removal of legends. A Purchaser may request that the Company remove, and the Company agrees to, authorize the removal of, any legend from such Securities, following the delivery by a Purchaser to the Company or the Company&#8217;s transfer agent of either a legended certificate representing such Securities or, if the Securities are issued in book-entry form, a written request for legend removal&#58; (i) following any sale of such Securities pursuant to Rule 144 or any other applicable exemption from the registration requirements under the Securities Act, (ii) if such Securities are eligible for sale under Rule 144(b)(1), or (iii) following the time that the Registration Statement is declared effective. If a legend removal request is made pursuant to the foregoing, the Company will, no later than two (2) Trading Days following the delivery by a Purchaser to the Company or the Company&#8217;s transfer agent of a legended certificate representing such Securities (or a request for legend removal, in the case of Securities issued in book-entry form), deliver or cause to be delivered to such Purchaser a certificate representing such Securities that is free from all restrictive legends or an equivalent book-entry position, as requested by the Purchaser. Certificates for Securities free from all restrictive legends may be transmitted by the Company&#8217;s transfer agent to a Purchaser by crediting the account of the Purchaser&#8217;s prime broker with the Depository Trust Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">DTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as directed by such Purchaser. The Company warrants that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement. If a Purchaser effects a transfer of the Securities in accordance with Section 5.11, the Company shall permit the transfer and shall promptly instruct its transfer agent to issue one or more certificates or credit shares to the applicable balance accounts at DTC in such name and in such denominations as specified by such Purchaser to effect such transfer. Each Purchaser hereby agrees that the removal of the restrictive legend pursuant to this Section 5.11 is predicated upon the Company&#8217;s reliance that such Purchaser will sell any such Securities pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and such Purchaser shall deliver a certificate reasonably satisfactory to the Company to the foregoing effect. Prior to the Company and its transfer agent agreeing to a form of representation letter to be given in connection with any legend removal opinion, the Company shall allow each Purchaser to review such form and shall cooperate, reasonably and in good faith, and accept reasonable comments thereto from the Purchasers&#59; and provided, further, that in no event shall the Purchaser be required to agree to indemnify, defend or hold harmless any Person. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restricted Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Such Purchaser understands that the Securities are characterized as &#8220;restricted securities&#8221; under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such Securities may be resold without registration under the Securities Act only in certain limited circumstances. Accordingly, such Purchaser represents that it is familiar with Rule 144 of the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">    Beneficial Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The purchase by the Purchaser of the Securities issuable to it at the Closing will not result in the Purchaser (individually or together with any other Person with whom the Purchaser has identified, or will have identified, itself as part of a &#8220;group&#8221; in a public filing made with the Commission involving the Company&#8217;s securities, where such aggregation would be made according to Section 13(d) of the Exchange Act) acquiring, or obtaining the right to acquire, in excess of 19.999% of the outstanding shares of Common Stock or the voting power of the Company on a post-transaction basis that assumes that such Closing shall have occurred. The Purchaser does not presently intend to, alone or together with others, make a public filing with the Commission to disclose that it has (or that it together with such other Persons have) acquired, or obtained the right to acquire, as a result of such Closing (when added to any other securities of the Company that it or they then own or have the right to acquire), in excess of 19.999% of the outstanding shares of Common Stock or the voting power of the Company on a post-transaction basis that assumes that each Closing shall have occurred.</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 6.&#160;&#160;&#160;&#160;REGISTRATION OF THE SECURITIES AND COMPLIANCE WITH THE SECURITIES ACT.</font></div><div style="text-indent:24.5pt"><font><br></font></div><div style="text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Registration Procedures and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Piggyback Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event that the Company, in its sole discretion, shall determine to prepare and file a registration statement on Form&#160;S-3,&#160;or any other appropriate form on which the Shares and Warrant Shares may be registered for resale (each of the Shares and Warrant Shares, together with any shares of capital stock issued or issuable, from time to time, upon any reclassification, share combination, share subdivision, stock split, share dividend or similar transaction or event or otherwise as a distribution on, in exchange for or with respect to any of the foregoing, in each case held at the relevant time by a Purchaser, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Registrable Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) by the Purchasers, whether or not on a continuous basis pursuant to Rule 415 under the Securities Act, which such registration statement may include shares that may be offered by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Subsequent Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and has not previously filed a Secondary Registration Statement (as defined below), the Company shall&#58; (i)&#160;notify each Purchaser of such determination&#59; and (ii)&#160;if, within ten (10)&#160;Business Days after receipt of such notice, any Purchaser requests in writing to include all or any part of its Registrable Securities in such Subsequent Registration Statement, include the Registrable Securities as so requested by the applicable Purchaser. Notwithstanding the foregoing and for avoidance of doubt, the Company may, but shall not be required to, file a Subsequent Registration Statement pursuant to this Agreement.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Secondary Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Company has not previously filed a Subsequent Registration Statement covering the resale on a continuous basis of the Registrable Securities, the Company shall prepare and file with the, on or before the date that is thirty (30) days after the Closing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Filing Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Commission a Registration Statement on Form&#160;S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on Form S-1) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Secondary Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#59; where used hereafter, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean either a Subsequent Registration Statement which includes the Registrable Securities and permits their resale on a continuous basis, or the Secondary Registration Statement, as applicable), relating to and providing for the resale of the Shares and Warrant Shares by the Purchasers on a continuous basis pursuant to Rule 415 under the Securities Act or, if Rule 415 is not available for offers and sales of the Registrable Securities, by such other means of distribution of Registrable Securities as the Holders may reasonably specify. Notwithstanding the foregoing, if the Commission prevents the Company from including any or all of the Registrable Securities on the Secondary Registration Statement due to limitations on the use of Rule 415 of the Securities Act for the resale of the Registrable Securities (and notwithstanding that the Company used diligent efforts to advocate with the staff of the Commission for the registration of all or a greater portion of the Registrable Securities), the Secondary Registration Statement shall register for resale such number of Registrable Securities that is equal to the maximum number of Registrable Securities as is permitted by the Commission. In such event, the number of Registrable Securities for which resale is to be registered for each selling shareholder named in the Secondary Registration Statement shall be reduced pro rata among all such selling shareholders and as promptly as practicable after being permitted to register additional Registrable Securities under Rule 415 under the Securities Act, the Company amend the Secondary Registration Statement or file one or more new registration statement(s) (such amendment or new registration statement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Remainder Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to register such additional Registrable Securities not included in the Secondary Registration Statement and cause such Remainder Registration Statement to become effective as promptly as practicable after the filing thereof, but in any event no later than 30 calendar days after the filing of such Remainder Registration Statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Remainder Effectiveness Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Remainder Effectiveness shall be extended to sixty (60) calendar days after the filing of such Remainder Registration Statement if the SEC notifies the Company that it will &#8220;review&#8221; such Remainder Registration Statement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, further, notwithstanding the foregoing, that the Company shall use reasonable best efforts to have such Remainder Registration Statement declared effective within five (5) business days after the date the Company is notified orally or in writing (whichever is earlier) by the Commission that such Remainder Registration Statement will not be reviewed or will not be subject to further review. Any failure by the Company to file the Secondary Registration Statement by the Filing Deadline or to effect the Secondary Registration Statement by the Effectiveness Deadline or the Remainder Registration Statement by the Remainder Effectiveness </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deadline shall not otherwise relieve the Company of its obligations to file or effect the Secondary Registration Statement or Remainder Registration Statement set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The Company shall use its reasonable best efforts, subject to receipt of necessary information from the Purchasers, to cause the Commission to declare a Registration Statement covering the Shares and Warrant Shares effective as soon as practicable after the date of the filing thereof and in any event no later than the earlier of (i) sixty (60)&#160;days after such filing if the Registration Statement has been filed on Form&#160;S-3,&#160;and no later than ninety (90)&#160;days after such filing if such Registration Statement has been filed on Form&#160;S-1, and in either case, no later than forty-five (45) days after such filing in the event the Registration Statement is not reviewed by the Commission and (ii) the fifth Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the Commission that the Registration Statement will not be reviewed or will not be subject to further review (in either case, such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Effectiveness Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;The Company shall promptly prepare and file with the Commission such amendments and supplements to the Registration Statement and the prospectus used in connection therewith as may be necessary to keep the Registration Statement effective until the earliest of (i)&#160;the third anniversary of the effective date of the Registration Statement, (ii)&#160;such time as all of the Shares and Warrant Shares purchased by the Purchasers pursuant to the terms of this Agreement have been sold pursuant to the Registration Statement, and (iii)&#160;such time as the Shares and Warrant Shares become eligible for resale by&#160;non-Affiliates&#160;without any volume limitations or other restrictions and without the current public information requirement pursuant to Rule 144(b)(1)(i) or any other rule of similar effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Notwithstanding the foregoing obligations, the Company may, upon written notice to the Purchasers, for a reasonable period of time, not to exceed forty-five (45) days in the case of clauses (A)&#160;and (B) below, or thirty (30) days in the case of clause (C)&#160;below (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Blackout Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and collectively not to exceed seventy-five (75) days, delay the filing of a Secondary Registration Statement or a request for acceleration of the effective date, or suspend the effectiveness of any Registration Statement, in the event that (A)&#160;the Company is engaged in any activity or transaction or preparations or negotiations for any activity or transaction that the Company desires to keep confidential for business reasons, if the Company&#8217;s Board of Directors determines in good faith that the public disclosure requirements imposed on the Company under the Securities Act in connection with the Registration Statement would require at that time disclosure of such activity, transaction, preparations or negotiations and such disclosure could result in material harm to the Company or its business transactions or activities, (B)&#160;the Company does not yet have appropriate financial statements of any acquired or to be acquired entities necessary for filing, either because such financial statements are not yet available or despite the Company using reasonable best efforts to procure such financial statements or (C)&#160;any other event occurs that makes any statement of a material fact made in such Registration Statement, including any document incorporated by reference therein, untrue or that requires the making of any additions or changes in the Registration Statement in order to make the statements therein not misleading&#59; provided, however, that in the case of a Blackout Period pursuant to clause (A)&#160;above, the Blackout Period shall terminate upon the earlier of (i) such&#160;forty-five (45) day period or (ii) the completion, resolution or public announcement of the relevant transaction or event. If the Company suspends the effectiveness of a Registration Statement pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.1(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Company shall, as promptly as reasonably practicable following the termination of the circumstance which entitled the Company to do so, take such actions as may be necessary to reinstate the effectiveness of such Registration Statement and give written notice to the Purchasers authorizing the Purchasers to resume offerings and sales pursuant to such Registration Statement. If as a result thereof the prospectus included in such Registration Statement has been amended or supplemented to comply with the requirements of the Securities Act, the Company shall enclose such revised prospectus with the notice to each Purchaser given pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company shall be entitled to exercise its rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.1(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> not more than once in any six (6)&#160;month period&#59; provided, however, that the aggregate number of days of all Blackout Periods hereunder shall not exceed seventy-five (75)&#160;days in any twelve (12)&#160;month period.  After the expiration of any Blackout Period and without further request from any Purchaser, the Company shall effect the filing (or if required amendment or supplement) of the Registration Statement, or the filing of other documents, as necessary to allow the Purchasers to resell the Registrable Securities as set forth herein. In providing to a Purchaser the written notice of a Blackout Period as contemplated by the first sentence of this Section 6.1(e), the Company </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall not (without the prior written consent of such Purchaser) disclose to such Purchaser any material nonpublic information giving rise to or otherwise associated with such Blackout Period.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;Upon notification by the Commission that the Registration Statement will not be reviewed or is not subject to further review by the Commission, the Company shall within three Business Days following the date of such notification request acceleration of such Registration Statement (with the requested effectiveness date to be not more than two Business Days later).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)    The Company shall furnish to the Purchasers with respect to the Shares and Warrant Shares registered under any Registration Statement (and to each underwriter, if any, of such Shares and Warrant Shares) such number of copies of prospectuses and such other documents as the Purchaser may reasonably request, in order to facilitate the public sale or other disposition of all or any of the Shares or Warrant Shares by the Purchaser.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;The Company shall bear all expenses in connection with the procedures in paragraphs (a)&#160;through (g) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and the registration of the Shares and Warrant Shares pursuant to the Registration Statement, other than fees and expenses, if any, of counsel or other advisers to the Purchasers or underwriting discounts, brokerage fees and commissions incurred by the Purchaser, if any in connection with the offering of the Shares and Warrant Shares pursuant to the Registration Statement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;In order to enable the Purchasers to sell the Shares and Warrant Shares under Rule 144, the Company shall use its reasonable best efforts to comply with the requirements of Rule 144, including use its reasonable best efforts to comply with the requirements of Rule 144(c)(1) with respect to public information about the Company and to timely file all reports required to be filed by the Company under the Exchange Act.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;The Company shall provide the Purchasers an opportunity to review and comment on all disclosures regarding the Purchasers and any plan of distribution proposed by them in connection with the preparation of any Registration Statement. Notwithstanding anything to the contrary contained herein, in no event shall the Company be permitted to name any Purchaser or Affiliate of a Purchaser as an &#8220;underwriter&#8221; without the prior written consent of such Purchaser&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that if the Commission requires that a Purchaser be identified as a statutory underwriter in either the Secondary Registration Statement or a Remainder Registration Statement, such Purchaser will have the option, in its sole and absolute discretion, to either (i) have the opportunity to withdraw from the Secondary Registration Statement or Remainder Registration Statement, as the case may be, upon its prompt written request to the Company or (ii) be included as such in the Secondary Registration Statement or Remainder Registration Statement, as the case may be.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restrictions on Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Purchaser agrees that it will not effect any disposition of the Securities that would constitute a sale within the meaning of the Securities Act or pursuant to any applicable state securities laws, unless and until (1)&#160;there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement or (2)&#160;such disposition is otherwise permitted by law, including pursuant to the procedures set forth in Rule 144 under the Securities Act or any other applicable exemption from the registration requirements under the Securities Act. Notwithstanding the preceding sentence, no restriction shall apply to a transfer by a Purchaser that is (i) a partnership transferring to its partners or former partners in accordance with partnership interests, or (ii) a limited liability company transferring to its members or former members in accordance with member interests.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. For the purpose of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; (i) the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Purchaser&#47;Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean any affiliate of the Purchaser, including, without limitation, any general partner or managing member of the Purchaser, any investment adviser of the Purchaser, or any transferee who is an affiliate of the Purchaser, and any person who controls the Purchaser or any affiliate of the Purchaser within the meaning of Section&#160;15 of the Securities Act or Section&#160;20 of the Exchange Act&#59; and (ii)&#160;the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall include any preliminary prospectus, final prospectus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), free writing prospectus, exhibit, supplement or amendment included in or relating to, and any document incorporated by reference in, the Registration Statement referred to in&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to indemnify and hold harmless the Purchasers and each Purchaser&#47;Affiliate, against any losses, claims, damages, liabilities or expenses, joint or several, that such Purchaser or Purchaser&#47;Affiliate incurs, under the Securities Act, the Exchange Act, or any other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company, such consent not to be unreasonably withheld or delayed), insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof as contemplated below)&#160;(i) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in the Registration Statement, including the Prospectus, financial statements and schedules, and all other documents filed as a part thereof or incorporated by reference therein, as amended at the time of effectiveness of the Registration Statement, including any information deemed to be a part thereof as of the time of effectiveness pursuant to paragraph (b)&#160;of Rule 430A under the Securities Act, or pursuant to Rules 430B, 430C or 434 under the Securities Act, or the Prospectus, in the form first filed with the Commission pursuant to Rule 424(b) under the Securities Act, or filed as part of the Registration Statement at the time of effectiveness if no Rule 424(b) filing is required or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state in any of them a material fact required to be stated therein or necessary to make the statements in the Registration Statement or any amendment or supplement thereto not misleading or in the Prospectus or any amendment or supplement thereto not misleading in light of the circumstances under which they were made, (ii) any violation or alleged violation by the Company or its agents of the Securities Act, the Exchange Act, or any other federal or state securities law or any rule or regulation thereunder, in connection with the performance or non-performance of its obligations under this Agreement or any action or inaction required of the Company in connection with any registration or (iii)&#160;arise out of or are based in whole or in part on any inaccuracy in the representations or warranties of the Company contained in this Agreement, breach of any covenant of the Company contained in this Agreement or any failure of the Company to perform its other obligations hereunder or under law, and will promptly reimburse each Purchaser and each Purchaser&#47;Affiliate for any legal and other&#160;out-of-pocket&#160;expenses as such expenses are reasonably incurred and documented by such Purchaser or such Purchaser&#47;Affiliate in connection with investigating, defending or preparing to defend, settling, compromising or paying any such loss, claim, damage, liability, expense or action&#59; provided, however, that the Company will not be liable for amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the written consent of the Company, which consent shall not be unreasonably withheld or delayed, and the Company will not be liable in any such case to the extent that any such loss, claim, damage, liability or expense arises out of or is based upon (i)&#160;an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, the Prospectus or any amendment or supplement thereto in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Purchaser expressly for use therein, or (ii)&#160;any statement or omission in any Prospectus that is corrected in any subsequent Prospectus that was delivered to the Purchaser prior to the pertinent sale or sales by the Purchaser.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Each Purchaser will severally, but not jointly, indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&#160;15 of the Securities Act or Section&#160;20 of the Exchange Act, against any losses, claims, damages, liabilities or expenses that the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person reasonably incurs, under the Securities Act, the Exchange Act, or any other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, but only if such settlement is effected with the written consent of such Purchaser, such consent not to be unreasonably withheld or delayed) insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof as contemplated below) arise out of or are based upon any untrue or alleged untrue statement of any material fact contained in the Registration Statement, the Prospectus, or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements in the Registration Statement or any amendment or supplement thereto not misleading or in the Prospectus or any amendment or supplement thereto not misleading in the light of the circumstances under which they were made, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, the Prospectus, or any amendment or supplement thereto, in reliance upon and in conformity with written information furnished </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to the Company by or on behalf of such Purchaser expressly for use therein&#59; and will reimburse the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person for any legal and other expense reasonably incurred by the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action&#59; provided, however, that (i)&#160;each Purchaser&#8217;s aggregate liability under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not exceed the amount of net proceeds received by such Purchaser on the sale of the Registrable Securities pursuant to the Registration Statement giving rise to such indemnification obligation,  and (ii) a Purchaser will not be liable for amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the written consent of such Purchaser, and (iii) a Purchaser will not be liable in any such case to the extent that any such loss, claim, damage, liability or expense arises out of or is based upon the gross negligence, fraud or willful misconduct of the Company, any of Company&#8217;s directors, any of Company&#8217;s officers who signed the Registration Statement or any person who controls the Company within the meaning of Section&#160;15 of the Securities Act or Section&#160;20 of the Exchange Act.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Promptly after receipt by an indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of notice of the threat or commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> promptly notify the indemnifying party in writing thereof, but the omission to notify the indemnifying party will not relieve it from any liability that it may have to any indemnified party for contribution or otherwise under the indemnity agreement contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to the extent it is not prejudiced as a result of such failure. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it may wish, jointly with all other indemnifying parties similarly notified, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party&#59; provided, however, if the defendants in any such action include both the indemnified party, and the indemnifying party and the indemnified party shall have reasonably concluded, based on an opinion of counsel reasonably satisfactory to the indemnifying party, that there may be a conflict of interest between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and&#47;or other indemnified parties that are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of its election to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&#160;the indemnified party shall have employed such counsel in connection with the assumption of legal defenses in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the expenses of more than one separate counsel, reasonably satisfactory to such indemnifying party, representing all of the indemnified parties who are parties to such action) or (ii)&#160;the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of action, in each of which cases the reasonable fees and expenses of counsel shall be at the expense of the indemnifying party. In no event shall any indemnifying party be liable in respect of any amounts paid in settlement of any action unless the indemnifying party shall have approved in writing the terms of such settlement&#59; provided that such approval shall not be unreasonably withheld or delayed. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of or consent to the entry of any judgment in any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnification could have been sought hereunder by such indemnified party, unless such settlement or judgment (x) includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding, (y) imposes no liability or obligation on the indemnified person and (z) does not include any admission of fault, culpability, wrongdoing or malfeasance by or on behalf of the indemnified person. The indemnifying party shall notify the indemnified party promptly of the institution, threat or assertion of any proceeding in connection with, arising out of, as a result of, relating to or based upon the transactions contemplated by this Agreement of which the indemnifying party is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such indemnified party and shall survive the transfer of any of the Securities by any of the Purchasers as permitted by this Agreement. Subject to the terms of this Agreement, all reasonable and documented fees and expenses of the indemnified party (including reasonable and documented fees and expenses to the extent incurred in connection with investigating or preparing to defend such proceeding in a manner not inconsistent with this Section 6.3) shall be paid to such indemnified party, as incurred, within ten Business Days of written notice thereof to the indemnifying party, provided that the indemnified party shall promptly reimburse the indemnifying party for that portion of such fees and expenses applicable to such actions for which such indemnified party is finally judicially determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;If the indemnification provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is required by its terms but is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party under paragraphs (a), (b) or (c)&#160;of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> in respect to any losses, claims, damages, liabilities or expenses referred to herein, then each applicable indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of any losses, claims, damages, liabilities or expenses referred to herein (i)&#160;in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnifying party, as well as any other relevant equitable considerations or (ii)&#160;if the allocation provided by clause (i)&#160;above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative fault referred to in clause (i)&#160;above but the relative benefits of the Company and the Purchaser. The relative benefits received by the Company on the one hand and each Purchaser on the other shall be deemed to be in the same proportion as the amount paid by such Purchaser to the Company pursuant to this Agreement for the Securities purchased by such Purchaser that were sold pursuant to the Registration Statement bears to the difference (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Difference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) between the amount such Purchaser paid for the Securities that were sold pursuant to the Registration Statement and the amount received by such Purchaser from such sale. The relative fault of the Company on the one hand and each Purchaser on the other shall be determined by reference to, among other things, whether the untrue or alleged statement of a material fact or the omission or alleged omission to state a material fact or the inaccurate or the alleged inaccurate representation and&#47;or warranty relates to information supplied by the Company or by such Purchaser and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in paragraph (c)&#160;of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in paragraph (c)&#160;of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> with respect to the notice of the threat or commencement of any threat or action shall apply if a claim for contribution is to be made under this paragraph (d)&#59; provided, however, that no additional notice shall be required with respect to any threat or action for which notice has been given under paragraph (c)&#160;for purposes of indemnification. The Company and the Purchaser agree that it would not be just and equitable if contribution pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> were determined solely by pro rata allocation (even if the Purchaser were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this paragraph. Notwithstanding the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, no Purchaser shall be required to contribute any amount in excess of the amount by which the Difference exceeds the amount of any damages that such Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&#160;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Purchasers&#8217; obligations to contribute pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are several and not joint.6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Information Available</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company, upon the reasonable request of a Purchaser, shall make available for inspection by such Purchaser, any deemed underwriter participating in any disposition pursuant to the Registration Statement and any attorney, accountant or other agent retained by the Purchasers or any deemed underwriter, all financial and other records, pertinent corporate documents and properties of the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Delay in Effectiveness of Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If (a)&#160;a Registration Statement covering the Shares and Warrant Shares is not filed on or prior to the Filing Deadline or declared effective by the Commission on or prior to the Effectiveness Deadline, then for each day following the Effectiveness </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deadline until but excluding the date the Company files or the Commission declares effective the Registration Statement, as the case may be, the Company shall, for each such day, pay each Purchaser with respect to any such failure, as liquidated damages and not as a penalty, an amount per&#160;thirty (30)-day&#160;period equal to 1.0% of the purchase price paid by such Purchaser for its Shares and Warrant Shares pursuant to this Agreement (calculated on a daily pro rata basis for any portion of such&#160;thirty (30)-day&#160;period prior to the cure of such failure)&#59; and for any such&#160;thirty (30)-day&#160;period (or earlier period if such failure is cured prior to thirty (30) days), such payment shall be made no later than three (3) Business Days following such&#160;thirty (30)-day&#160;period (or earlier period if such failure is cured prior to thirty (30)&#160;days). Notwithstanding the foregoing provisions, in no event shall the Company be obligated to pay any liquidated damages pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to more than one Purchaser in respect of the same Shares or Warrant Shares for the same period of time or in an aggregate amount that exceeds 6.0% of the purchase price paid by the Purchasers for the Shares and Warrant Shares pursuant to this Agreement. Such payments shall be made to the Purchasers in cash.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 7.&#160;&#160;&#160;&#160;NO BROKER&#8217;S FEE.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company hereby represents to the Purchasers that no broker, investment banker, financial advisor or other individual, corporation, general or limited partnership, limited liability company, firm, joint venture, association, enterprise, joint securities company, trust, unincorporated organization or other entity is entitled to any broker&#8217;s, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission in connection with the transactions contemplated by this Agreement, other than fees payable by the Company to the Placement Agents, which will be paid by the Company. The Company further agrees to indemnify each Purchaser for any claims, losses or expenses incurred by any such Purchaser as a result of the representation in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> being untrue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 8.&#160;&#160;&#160;&#160;COVENANTS.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Form D&#59; Blue Sky Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D of the Securities Act. The Company will take such action as the Company shall reasonably determine is necessary in order to obtain an exemption from, or to qualify the Securities for, sale to the Purchasers at the Closing pursuant to this Agreement under applicable securities or &#8220;Blue Sky&#8221; laws of the states of the United States, and shall provide evidence of such actions promptly upon the written request of any Purchaser.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transfer Taxes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;On the Closing Date, all stock transfer, stamp or other taxes (other than income taxes) that are required to be paid in connection with the issuance, sale and delivery of the Securities to the Purchasers hereunder will be fully paid or provided for by the Company and all laws imposing such taxes will have been fully complied with and the Purchasers and their respective Affiliates shall have no obligation therefor.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Listing of Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company shall promptly secure the listing of the Shares and Warrant Shares upon each national securities exchange and automated quotation system that requires an application by the Company for listing, if any, upon which shares of Common Stock are then listed (subject to official notice of issuance) and shall maintain such listing, so long as any other shares of Common Stock shall be so listed. The Company shall use its reasonable best efforts to maintain the Common Stock&#8217;s listing on the Trading Market. The Company shall use reasonable best efforts to comply in all respects with the Company&#8217;s reporting, filing and other obligations under the bylaws or rules of any such national securities exchange or automated quotation system. The Company shall pay all fees and expenses in connection with satisfying its obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Public Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither the Company nor any Person acting on its behalf has provided the Purchasers with any information that will constitute material, non-public information as of the Disclosure Time.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reservation of Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Warrant Shares that are issuable upon the exercise of the Warrants.</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.6   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equal Treatment of Purchasers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> No consideration (including any modification of documents related hereto) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement or any documents related hereto unless the same consideration is also offered to all Purchasers hereunder. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class (subject to the proviso in the preceding sentence) and shall not in any way be construed as the Purchasers acting in concert or as a group (including a &#8220;group&#8221; within the meaning of Section 13(d)(3) of the Exchange Act) with respect to the purchase, disposition or voting of securities or otherwise. The Company does not have, and will not enter into, any agreement or understanding with any Purchaser that affords such Purchaser any rights or terms with respect to the transactions contemplated by this Agreement (including the exhibits hereto) that are more beneficial to such Purchaser than those afforded to all other Purchasers hereunder.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pledge of Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company acknowledges and agrees that a Purchaser&#8217;s Shares or Warrant Shares, as applicable, may be pledged by a Purchaser in connection with a bona fide margin agreement or other loan or financing arrangement that is secured by the Shares or the Warrant Shares, as applicable. The pledge of Shares or Warrant Shares, as applicable, shall not be deemed to be a transfer, sale or assignment of the Shares hereunder, and no Purchaser effecting a pledge of Shares or Warrant Shares, as applicable, shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement&#59; provided that a Purchaser and its pledgee shall be required to comply with the provisions of this Agreement in order to effect a sale, transfer or assignment of Shares or Warrant Shares, as applicable, to such pledgee. </font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Adjustments in Share Numbers and Prices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event of any stock split, subdivision, dividend or distribution payable in shares of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), combination or other similar recapitalization or event occurring after the date hereof and prior to the Closing, each reference this Agreement to a number of shares or a price per share shall be deemed to be amended to appropriately account for such event.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subsequent Equity Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. From the date hereof until the earlier of (i) the date the Registration Statement is declared effective by the Commission, and (ii) ninety (90) days after the Closing Date, neither the Company nor any subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents. Notwithstanding the foregoing, this Section 8.9 shall not apply in respect of an Exempt Issuance.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 9.&#160;&#160;&#160;&#160;NOTICES.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed facsimile or electronic mail, or mailed by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of facsimile or electronic mail transmission (provided that the notice shall not be deemed given if the sender receives an automatic system-generated response that such electronic mail was undeliverable), or when so received in the case of mail or courier, and addressed as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;if to the Company, to&#58;</font></div><div style="margin-top:12pt;padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gossamer Bio, Inc.</font></div><div style="padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3013 Science Park Road</font></div><div style="padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego, CA 92121</font></div><div style="padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58; Bryan Giraudo</font></div><div style="padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; bgiraudo&#64;gossamerbio.com</font></div><div style="padding-left:79.55pt;text-align:justify"><font><br></font></div><div style="padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with a copy to (which shall not constitute notice)&#58;</font></div><div style="padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jeff Boerneke</font></div><div style="padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; jboerneke&#64;gossamerbio.com</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;with a copy to (which shall not constitute notice)&#58;</font></div><div style="margin-top:12pt;padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Latham &#38; Watkins LLP</font></div><div style="padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12670 High Bluff Drive</font></div><div style="padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego, CA 92130</font></div><div style="padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58;&#160;Matthew T. Bush</font></div><div style="padding-left:79.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; matt.bush&#64;lw.com</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or to such other Person at such other place as the Company shall designate to the Purchasers in writing&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;if to the Purchasers, to the applicable address set forth on the signature pages hereof or to such other Person at such other place as the Purchasers shall designate to the Company in writing.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 10.&#160;&#160;&#160;&#160;MISCELLANEOUS.</font></div><div style="text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Waivers and Amendments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Neither this Agreement nor any provision hereof may be changed, waived, discharged, terminated, modified or amended except upon the written consent of the Company and the Purchasers holding at least two-thirds of the Securities issued hereunder and then-held by all Purchasers, in the case of any change, discharge, termination, modification, or of the party hereto against whom the waiver is to be effective, in the case of a waiver, provided that (a) if any amendment or waiver disproportionately and adversely affects a Purchaser (or a subset of Purchasers) in any material respect, the consent of such disproportionately affected Purchaser (or each Purchaser within such subset of Purchasers) shall also be required and (b) the consent of each Purchaser shall be required for any change in the Purchase Price, any change in the type of security to be issued to Purchasers at Closing, or the amendment, modification or waiver of this Section 10.1, of Section 10.14 or of any of the closing conditions set forth in Sections 3.2(b)(i) or 3.2(b)(v). No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing wavier in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. The failure of any party at any time to require another party&#8217;s performance of any obligation under this Agreement shall not affect the right subsequently to require performance of that obligation.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Headings&#59; Interpretation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be part of this Agreement. The terms &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to this Agreement as a whole and not to any particular provision of this Agreement. All section, paragraph or clause references not attributed to a particular document shall be references to such parts of this Agreement, and all exhibit, annex, letter and schedule references not attributed to a particular document shall be references to such exhibits, annexes, letters and schedules to this Agreement. Except when used together with the word &#8220;either&#8221; or otherwise for the purpose of identifying mutually exclusive alternatives, the term &#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;and&#47;or.&#8221; All references in this Agreement to &#8220;dollars&#8221; or &#8220;$&#8221; shall mean United States dollars. Except where the context otherwise requires, wherever used the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders. The term &#8220;including&#8221; or &#8220;includes&#8221; means &#8220;including without limitation&#8221; or &#8220;includes without limitation.&#8221; Any references to any agreement, document or instrument shall be deemed to refer to such agreement, document or instrument as amended, supplemented or modified from time to time. For purposes of Section 4, references to the Company shall be deemed to include the Company and its subsidiaries.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. To the extent permitted by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Survival.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;The representations and warranties contained herein shall survive the Closing and the delivery of the Securities. The agreements and covenants contained herein shall survive for the applicable statute of limitations.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governing Law&#59;&#160;Jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;This Agreement (including all matters concerning the construction, validity, enforcement and interpretation hereof) shall be governed by and interpreted in accordance with the internal laws of the State of New York. Any and all disputes arising out of, concerning, or related to this Agreement, or to the interpretation, performance, breach or termination thereof shall be referred to and resolved by the federal courts located in New York, New York or, to the extent no such court does not have subject matter jurisdiction, the state courts of the State of New York located in New York, New York (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Specified Courts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each of the parties hereto irrevocably and unconditionally submits to the exclusive jurisdiction of the Specified Courts, waives any objection to the laying of venue of any suit, action or proceeding brought in such courts and waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT (INCLUDING THE EXHIBITS HERETO), THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE&#160;ALL-ENCOMPASSING&#160;OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;This Agreement may be executed in counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument. Signatures to this Agreement transmitted by facsimile, by email (including &#8220;portable document format&#8221; (&#8220;.pdf&#8221;), or by any other electronic means complying with the U.S. ESIGN Act of 2000 or the New York Electronic Signatures and Records Act, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. None of the Purchasers may assign this Agreement or any rights or obligations hereunder, in whole or in part, without the prior written consent of the Company, such consent not to be unreasonably withheld, conditioned or delayed&#59; provided, however, that a Purchaser may assign its rights and delegate its duties hereunder in whole or in part to an Affiliate or to a third party acquiring some or all Securities in a transaction complying with applicable securities laws without the prior written consent of the Company, provided such assignee agrees in writing to be bound by the provisions hereof that apply to Purchasers. The Company may not assign this Agreement or any rights or obligations hereunder, in whole or in part, without the prior written consent of all Purchasers. Without limiting the generality of the foregoing, in the event that the Company is a party to a merger, consolidation, share exchange or similar business combination transaction in which the Common Stock is converted into the equity securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term &#8220;Company&#8221; shall be deemed to refer to such Person and the term &#8220;Shares&#8221;, &#8220;Warrants&#8221;, or &#8220;Warrant Shares&#8221; shall be deemed to refer to the securities received by the Purchasers in exchange therefor in connection with such transaction. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective permitted successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third-Party Beneficiaries.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;The Placement Agents shall be the third-party beneficiaries of the representations and warranties of the Company in Section 4 and the representations, warranties and covenants of the Purchasers in Section 5 of this Agreement. This Agreement is intended for the benefit of the parties hereto and the Placement Agents and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;10.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Entire Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;This Agreement and the other documents and instruments delivered pursuant hereto or thereto, including the exhibits and schedules hereto or thereto, constitute the full and entire understanding and agreement between the parties hereto with regard to the subjects hereof and thereof and supersede all prior agreements, understandings and representations, both oral and written, between the parties with respect to the subject matter hereof and thereof.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Independent Nature of Purchasers&#8217; Obligations And Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;The obligations of each Purchaser under this Agreement are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under this Agreement. The decision of each Purchaser to purchase Securities pursuant to this Agreement has been made by such Purchaser independently of any other Purchaser. Nothing contained herein and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group (within the meaning of Section 13(d) of the Exchange Act or otherwise), or are deemed affiliates (as such term is defined under the Exchange Act) with respect to such obligations or the transactions contemplated by this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights, including the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser acknowledges (i) that it is not relying upon any Person other than the Company and its officers and directors, in making its investment or decision to invest in the Company and (ii) no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment in the Securities or enforcing its rights hereunder. Each Purchaser agrees that no Purchaser nor the respective controlling persons, officers, directors, partners, agents, or employees of any Purchaser shall be liable to any other Purchaser for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase of the Securities. The Company acknowledges that each of the investors has been provided with the same Agreement for the purpose of closing a transaction with multiple purchasers and not because it was required or requested to do so by any Purchaser. It is expressly understood that each provision contained in this Agreement is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Fees and Expenses.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as otherwise provided herein or in the other documents or instruments contemplated hereby, each of the Company and the Purchasers shall bear its own expenses and legal fees incurred on its behalf with respect to this Agreement and the transactions contemplated hereby. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney&#8217;s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Further Actions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Each party hereto agrees to execute, acknowledge, and deliver such further instruments, and to do all such other reasonable acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement and to evidence the fulfillment of the agreements herein contained.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Form 8-K&#59; Disclosure of the Transactions and other Material Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Company shall at or before the Disclosure Time, issue one or more press releases (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or file with the Commission a Current Report on Form 8-K (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Disclosure Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), disclosing any material non-public information within the meaning of the federal securities laws that the Company, or any of its officers, directors, employees, agents or any other Person, including the Placement Agents, acting at its direction or on its behalf has provided to the Purchasers in connection with the </font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">transactions contemplated by this Agreement prior to the filing of the Disclosure Document (which includes the material terms of the transactions contemplated hereby and any other information made available to the Purchasers). The Company shall, by 5&#58;30 p.m. (New York City time) on the fourth Trading Day following the date hereof file with the Commission a Current Report on Form 8-K disclosing the material terms of the transactions contemplated hereby, which shall include as an exhibit this Agreement. From and after the issuance of the Disclosure Document, neither the Company nor any of its officers, directors, employees, agents or any other Person, including the Placement Agents, acting at its direction or on its behalf shall provide any material, nonpublic information to any Purchaser, unless otherwise specifically agreed in writing by such Purchaser, except in the case of material, nonpublic information provided to an observer or member of the Company&#8217;s board of directors or who is affiliated with such Purchaser. The Company shall not, and shall cause its officers, directors, employees, agents and any other Person, including the Placement Agents, acting at its direction or on its behalf not to, publicly disclose the name of any Purchaser or any Affiliate or investment advisor of any Purchaser, or include the name of any Purchaser or any Affiliate or investment advisor of any Purchaser without the prior written consent (including by e-mail) of such Purchaser (i) in any press release or marketing materials, or (ii) in any filing with the Commission or any regulatory agency or trading market, except (A) as required by the federal securities laws, rules or regulations, (B) to the extent such disclosure is required by other laws, rules or regulations, at the request of the staff of the Commission or regulatory agency or under regulations of any national securities exchange or other trading market on which the Company&#8217;s securities are listed or designated for trading or (C) to the extent such disclosure contains only information previously approved in accordance with this Section 10.13, and in the case of any disclosure made pursuant to clause (ii), the Company will provide the Purchaser with prior written notice (including by e-mail) of the applicable portion of such filing. Upon the earlier of the (i) the Disclosure Time and (ii) the earlier of the issuance or filing, as applicable, of the Disclosure Document, each Purchaser shall no longer be subject to any confidentiality or similar obligations under any current agreement, whether written or oral, with the Company or any of its respective officers, directors, Affiliates, employees or agents, or any other Person, including the Placement Agents, acting at its direction or on its behalf. The Company understands and confirms that the Purchasers and their respective Affiliates will rely on the foregoing representations in effecting transactions in securities of the Company.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> This Agreement may be terminated by any Purchaser, as to such Purchaser&#8217;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated within ten calendar days from the Effective Date through no fault of such Purchaser&#59; provided, however, that no such termination will affect the right of any party to sue for any breach by the other party (or parties), and, upon such termination pursuant to this Section 10.15, any purchase price wired to the Company by a Purchaser shall be promptly returned to the Purchaser, but in no event later than the first Trading Day following such termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Remedies.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Each party hereto acknowledges that, in view of the uniqueness of the securities referenced herein and the transactions contemplated by this Agreement, the other parties would not have an adequate remedy at law for money damages in the event that this Agreement has not been performed in accordance with its terms, and therefore agrees that, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, the other parties shall be entitled to specific performance and injunctive or other equitable relief, without the necessity of proving the inadequacy of monetary damages as a remedy or the posting of a bond.</font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arm&#8217;s Length Transaction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Company acknowledges and agrees that (i) the transactions described in this Agreement are an arm&#8217;s-length commercial transaction between the parties, (ii) the Purchasers have not assumed nor will they assume an advisory or fiduciary responsibility in the Company&#8217;s favor with respect to any of the transactions contemplated by this Agreement or the process leading thereto, and the Purchasers have no obligation to the Company with respect to the transactions contemplated by this Agreement except those obligations expressly set forth in this Agreement, (iii) any advice given by any of the Purchasers or any of their respective representatives or agents in connection with the transactions described in this Agreement is merely incidental to such Purchaser&#8217;s purchase of its Securities, and (iv) the Company&#8217;s decision to enter into the this Agreement has been based solely on the independent evaluation by the Company and its representatives.</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;signature pages follow&#93;</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="i5c2a5795721c4b79a1bbda1f19d78c53_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the parties hereto have caused this Agreement to be executed by their duly authorized representatives as of the day and year first above written.</font></div><div style="text-indent:24.5pt"><font><br></font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPANY&#58;</font></div><div style="padding-left:220.5pt"><font><br></font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GOSSAMER BIO, INC.</font></div><div style="padding-left:220.5pt"><font><br></font></div><div style="padding-left:220.5pt"><font><br></font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;Faheem Hasnain&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:238.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;Faheem Hasnain</font></div><div style="padding-left:238.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:280.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.224%"><tr><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.371%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-indent:24.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT&#93;</font></div><div style="margin-top:12pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the parties hereto have caused this Agreement to be executed by their duly authorized representatives as of the day and year first above written.</font></div><div><font><br></font></div><div style="text-indent:24.5pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PURCHASER&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;       ___________________________________</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;<br>Title&#58;  &#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address for Notice to Purchaser&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address for Delivery of Securities <br>to Purchaser (if not same as <br>address for notice)&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br><br>&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Warrant Shares&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial Ownership Blocker &#9633; 4.99% or &#9633; 9.99% or &#9633; 14.99% or &#9633; 19.99%</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EIN Number&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT&#93;</font></div><div style="margin-top:12pt"><font><br></font></div><div><font><br></font></div></div></div><div id="i5c2a5795721c4b79a1bbda1f19d78c53_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;Form of Warrant&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div><div><font><br></font></div></div></div><div id="i5c2a5795721c4b79a1bbda1f19d78c53_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lock-Up Agreement</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gossamer Bio, Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">July 19, 2023</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Leerink Partners LLC</font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1301 Avenue of the Americas, 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Floor</font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New York, New York 10019</font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font><br></font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Piper Sandler &#38; Co.</font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800 Nicollet Mall, Suite 900</font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Minneapolis, Minnesota 55402</font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font><br></font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">H.C. Wainwright &#38; Co., LLC</font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">430 Park Avenue, 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Floor</font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New York, New York 10022</font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:46.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Re&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Gossamer Bio, Inc. - Lock-Up Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ladies and Gentlemen&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The undersigned understands that you, as placement agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Placement Agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), propose to conduct a private placement pursuant to that certain Securities Purchase Agreement by and among Gossamer Bio, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and the purchasers named therein, dated as of July 19, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), providing for the sale and issuance of (i) shares of the Company&#8217;s Common Stock and (ii) warrants to purchase shares of the Company&#8217;s Common Stock. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Purchase Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In consideration of the entry into the Purchase Agreement, and of other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period beginning on the date hereof and continuing to, and including, the date 90 days after the date of the Purchase Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Lock-Up Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the undersigned shall not, without the prior written consent of Leerink Partners LLC, subject to the exceptions set forth below&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of the Company&#8217;s Common Stock or any securities convertible into or exercisable or exchangeable for the Company&#8217;s Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Lock-Up&#160;Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), or publicly disclose the intention to make any offer, sale, pledge or disposition of any Lock-Up Shares&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the&#160;Lock-Up&#160;Shares, whether any such transaction described in clause (1)&#160;above or this clause (2)&#160;is to be settled by delivery of&#160;Lock-Up&#160;Shares or such other securities, in cash or otherwise, in each case other than&#58;</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(A) transfers of the&#160;Lock-Up&#160;Shares as a bona fide gift or gifts,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(B) transfers or dispositions of the&#160;Lock-Up&#160;Shares to any trust for the direct or indirect benefit of the undersigned,</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(C) distributions by a trust to its beneficiaries,</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(D) transfers or dispositions of the&#160;Lock-Up&#160;Shares to any corporation, partnership, limited liability company or other entity, all of the beneficial ownership interests of which are held by undersigned,</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(E) transfers or dispositions of the&#160;Lock-Up&#160;Shares by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of undersigned,</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(F) transfers of the&#160;Lock-Up&#160;Shares to partners, members or stockholders of the undersigned, or to another partnership, limited liability company, corporation or other business entity that controls, is controlled by or is under common control with the undersigned&#59;</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(G) if the undersigned is an investment company registered under the Investment Company Act of 1940, as amended (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Mutual Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), pursuant to a merger or reorganization with or into another Mutual Fund that shares the same investment adviser registered pursuant to the requirements of the Investment Advisers Act of 1940, as amended&#59;</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(H) any transfers pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction, approved by the board of directors of the Company, made to all holders of Common Stock involving a change of control of the Company, provided that, in the event that such tender offer, merger, consolidation or other similar transaction is not completed, any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock held by the undersigned shall remain subject to the restrictions on transfer set forth herein&#59;</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(I)  transfers to the Company as forfeitures to satisfy tax withholding and remittance obligations of the undersigned in connection with the exercise or vesting of equity awards granted pursuant to the Company&#8217;s equity incentive plans or transfers to the Company pursuant to a net exercise or cashless exercise by the stockholder of outstanding equity awards pursuant to the Company&#8217;s equity incentive plans&#59; provided the Common Stock issued shall remain subject to the restrictions on transfer set forth in this agreement and any filing under Section 16 of the Exchange Act made during the Lock-Up Period shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause&#59;</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(J)  transfers to the Company pursuant to any contractual arrangement that provides for the repurchase by the Company or forfeiture of the undersigned&#8217;s Common Stock in connection with the termination of the undersigned&#8217;s service to the Company&#59; provided that if the undersigned is required to file a report under Section 16 of the Exchange Act reporting a reduction in beneficial ownership of shares of Common Stock during the Lock-Up Period, the undersigned shall clearly indicate in the footnotes thereto that the filing relates to the termination of the undersigned&#8217;s employment or other services&#59;</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">provided that (x)&#160;in the case of any transfer or distribution pursuant to clauses (A) &#8211; (G), each transferee, donee or distributee shall execute and deliver to the Company a&#160;lock-up&#160;letter in the form of this letter agreement&#59; and (y)&#160;in the case of any transfer, disposition or distribution pursuant to clause (A) &#8211; (F), any such transfer or distribution shall not involve a disposition for value. For purposes of this agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything herein to the contrary, nothing herein shall prevent the undersigned from establishing a 10b5-1 trading plan that complies with Rule 10b5-1 under the Exchange Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">10b5-1 Trading Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or from amending an existing 10b5-1 Trading Plan so long as there are no sales of Shares under such plan during the Lock-Up Period&#59; and provided that, the establishment of a 10b5-1 Trading </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Plan or the amendment of a 10b5-1 Trading Plan, in either case, providing for sales of Lock-Up Shares shall only be permitted if (i) the undersigned does not otherwise voluntarily effect any public filing or report regarding the establishment or amendment of such plan and (ii) if any filing under the Exchange Act or other public announcement shall be legally required during the Lock-Up Period, such filing or public announcement shall indicate that no transfers under such trading plans will take place during the Lock-Up Period.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This letter agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provisions hereof be enforced by, any other Person.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The undersigned understands that the undersigned shall be released from all obligations under this letter agreement if the Purchase Agreement shall terminate or be terminated prior to the Closing.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This letter agreement and any claim, controversy or dispute arising under or related to this agreement shall be governed by and construed in accordance with the laws of the State of New York.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> &#91;signature page follows&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div><div><font><br></font></div></div></div><div id="i5c2a5795721c4b79a1bbda1f19d78c53_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:10.95pt;padding-left:226.8pt;text-align:justify;text-indent:-226.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="margin-bottom:10.95pt;padding-left:226.8pt;text-align:justify;text-indent:-226.8pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">IF AN INDIVIDUAL&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">IF AN ENTITY&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(duly authorized signature)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">(please print complete name of entity)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">(please print full name)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(duly authorized signature)</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">(please print full name)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:22.5pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:8.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(please print full title)</font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10.95pt;padding-left:226.8pt;text-align:justify;text-indent:-226.8pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Lock-Up Agreement&#93;</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>goss-2023x0719xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i87a238fe2e1444be92770e398a655d62_1"></div><div style="min-height:72pt;width:100%"><div style="padding-right:-18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 99.1</font></div></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:72px;margin-bottom:5pt;vertical-align:text-bottom;width:151px"></div><div style="padding-right:-18pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Gossamer Bio Announces $212 Million Private Placement Financing</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">- In Conjunction with Offering, Interim TORREY OLE Data and PROSERA Phase 3 Design Disclosed via 8-K&#59; Conference Call to Discuss Data and Phase 3 Design with Leading PAH KOLs to be Held on July 25</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> - </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SAN DIEGO &#8211; July 20, 2023 &#8211; Gossamer Bio, Inc. (Nasdaq&#58; GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement for gross proceeds of approximately $212 million, before deducting placement agent fees and offering expenses.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The financing includes participation from new and existing institutional investors, including New Enterprise Associates (NEA), EcoR1 Capital, Armistice Capital, Farallon, Madison Avenue Partners, LP., Nantahala, Samsara BioCapital, SilverArc Capital, Octagon Capital, Boxer Capital, Invus, the Federated Hermes Kaufmann Funds, Palo Alto Investors LP, and Rock Springs Capital, and certain directors and executive officers of Gossamer. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the private placement, Gossamer is selling 129,869,440 shares of its common stock and accompanying warrants to purchase up to 32,467,360 shares of common stock, at a combined price of $1.63125 per share of common stock and accompanying warrant (or a combined price of $1.85125 per share and accompanying warrant for participating officers and directors).  The warrants will have an exercise price of $2.04 per share of common stock, will be immediately exercisable and expire on July 24, 2028. The private placement is expected to close on July 24, 2023, subject to customary closing conditions. The financing was priced at-the-market under Nasdaq rules.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gossamer intends to use the net proceeds from the private placement to fund the ongoing development and commercialization of seralutinib and for working capital and general corporate purposes.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;We are grateful for the support from this investor syndicate and thrilled to embark on the registrational PROSERA Phase 3 trial, the next step towards bringing seralutinib to patients with PAH,&#8221; said Faheem Hasnain, Co-Founder, Chairman and CEO of Gossamer. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition to announcing this financing, Gossamer today disclosed via 8-K an interim update of its TORREY open-label extension (OLE) data and details of the design of the PROSERA study. A conference call to discuss this information with global PAH leaders, Dr. Ray Benza, Dr. Ardi Ghofrani, and Dr. Jim White will be held on Tuesday, July 25</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> at 10&#58;00 a.m. EDT. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The live audio webcast may be accessed through the &#8220;Events &#47; Presentations&#8221; page in the &#8220;Investors&#8221; section of the Company's website at </font><font style="color:#0000ff;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">www.gossamerbio.com</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Alternatively, the conference call may be accessed through the following&#58;</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date &#47; Time&#58;  July 25, 10&#58;00 a.m. EDT</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Domestic Dial-in Number&#58; 1-800-285-6670</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">International Dial-in Number&#58; 713-481-0091</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Conference Reference&#58; Seralutinib Program Update Call</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Live Webcast&#58; </font><font style="color:#0000ff;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;edge.media-server.com&#47;mmc&#47;p&#47;qzyj9utp</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-right:-18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 99.1</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A replay of the audio webcast will be available for 30 days on the &#8220;Investors&#8221; section of the Company's website, </font><font style="color:#0000ff;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">www.gossamerbio.com</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Leerink Partners is acting as lead placement agent for the private placement. H.C. Wainwright &#38; Co. is acting as co-placement agent. Piper Sandler and Wedbush PacGrow are acting as capital markets advisors to Gossamer Bio.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The securities described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Gossamer has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock and shares of common stock issuable upon the exercise of the warrants issued in this private placement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. </font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-right:-18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 99.1</font></div></div><div style="margin-bottom:12pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Gossamer Bio</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Forward Looking Statements </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company&#8217;s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements related to the timing, size and expectation of the closing of the private placement, expectations regarding market conditions, the satisfaction of customary closing conditions related to the private placement and the anticipated use of proceeds therefrom, and plans to embark on the PROSERA study. Such forward-looking statements involve substantial risks and uncertainties that could cause our actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer&#8217;s business, including, without limitation&#58; the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed financing&#59; and other risks described in the Company&#8217;s prior press releases and the Company&#8217;s filings with the Securities and Exchange Commission (SEC), including under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-right:-18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 99.1</font></div></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:100%">For Investors and Media&#58;</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bryan Giraudo, Chief Operating Officer and Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gossamer Bio Investor Relations</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ir&#64;gossamerbio.com </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>goss-20230719.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:91a53403-3a34-43fc-84d5-df82498874be,g:c7abaad3-4801-48e8-9286-81ab07d36851-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:goss="http://www.gossamerbio.com/20230719" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gossamerbio.com/20230719">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="goss-20230719_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="goss-20230719_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.gossamerbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>goss-20230719_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:91a53403-3a34-43fc-84d5-df82498874be,g:c7abaad3-4801-48e8-9286-81ab07d36851-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_9ca5c6e3-4759-4f36-bd8d-845f57905acf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c10d38d6-65c2-4668-9830-0c7396302d48_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_935bb508-ffca-4a1d-bfde-d5851e1a0bb9_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a684c4e9-95af-495c-822b-b48212b1b67b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6d1361cf-d5d3-40c0-a5a4-8ca9895ba7ec_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_92e532bf-5692-497a-81e2-93076ad8b9b1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_02ecfc7e-2d03-45c4-bf9f-443161c6874e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_cde1a844-2d22-47f4-99dd-378b07597b2c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_30c5f81d-0633-4b18-92b4-d352a91915f8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f70d7a12-c998-4718-a056-64464d0a551d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_3c21d965-b047-4ba5-960c-8b651630ff6f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_8b08d052-16f6-4f4b-8952-cb4595faf5f8_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_41e8724f-0d33-4ed2-be72-ffd15910fbe6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_61a1c489-b4c2-4e14-8f06-f13eaa7f3d2e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f141f96c-6d2d-4d1d-9231-500f1dbb9827_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_97b13b52-19c3-419f-943e-ed144d25a464_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f87ca28d-7d7a-4ca0-9067-16343b95b219_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e62696f3-2c7e-4aa8-82e6-c4830113b224_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_90e314f7-44a6-4ae7-bde9-7db423deaadb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2a685865-d4c3-41e2-9f94-86ab50c2a69e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_64d5c49e-1e3c-4c9b-9ecd-86cde6300d87_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4dc527b2-1911-4974-9f17-49dc41ba6a6b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>goss-20230719_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:91a53403-3a34-43fc-84d5-df82498874be,g:c7abaad3-4801-48e8-9286-81ab07d36851-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gossamerbio.com/role/Cover" xlink:type="simple" xlink:href="goss-20230719.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e1765f20-1753-452b-b093-32eae35006d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_DocumentType_e1765f20-1753-452b-b093-32eae35006d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_24cbe3b7-55f6-4308-9828-388e15d559b9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_DocumentPeriodEndDate_24cbe3b7-55f6-4308-9828-388e15d559b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_97ab903a-1030-4245-8cc7-c06e235e9bcc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_EntityRegistrantName_97ab903a-1030-4245-8cc7-c06e235e9bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1cefaee4-0842-453a-ba18-950f9452ea5a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1cefaee4-0842-453a-ba18-950f9452ea5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_87065c50-c60e-4ae0-81a2-32843e4ba17b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_EntityFileNumber_87065c50-c60e-4ae0-81a2-32843e4ba17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ef29e2b8-a805-4f38-a569-1a2d467f5f17" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_EntityTaxIdentificationNumber_ef29e2b8-a805-4f38-a569-1a2d467f5f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_495a1000-074a-45e2-aab8-0bc8dc72ca00" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_EntityAddressAddressLine1_495a1000-074a-45e2-aab8-0bc8dc72ca00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_087d1669-f498-4617-9e31-c6884fed7f40" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_EntityAddressCityOrTown_087d1669-f498-4617-9e31-c6884fed7f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_630cc454-a434-4254-addc-7ca3d07e094b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_EntityAddressStateOrProvince_630cc454-a434-4254-addc-7ca3d07e094b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7f2a927c-bcda-489c-818c-60d2a93fb72b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_EntityAddressPostalZipCode_7f2a927c-bcda-489c-818c-60d2a93fb72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_57287e04-d8dc-4de9-9a6a-22de8260675c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_CityAreaCode_57287e04-d8dc-4de9-9a6a-22de8260675c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8a1c301d-c55f-4069-a320-9943fc7aa0ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_LocalPhoneNumber_8a1c301d-c55f-4069-a320-9943fc7aa0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d754db56-df9f-4ec8-95ff-c2ee6362071d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_WrittenCommunications_d754db56-df9f-4ec8-95ff-c2ee6362071d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_53472c32-78c9-4b4a-aecd-9051ecd5f338" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_SolicitingMaterial_53472c32-78c9-4b4a-aecd-9051ecd5f338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_2f3879ae-8d62-4230-bae7-661a6d69ebf0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_PreCommencementTenderOffer_2f3879ae-8d62-4230-bae7-661a6d69ebf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_dad7ec8c-6fef-4614-bae5-7788f0c51f93" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_dad7ec8c-6fef-4614-bae5-7788f0c51f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0a99a29b-79b2-43a9-abad-62eedf7d853c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_Security12bTitle_0a99a29b-79b2-43a9-abad-62eedf7d853c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ebf2aa16-a1fe-4f82-9f6b-b9515092c39c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_TradingSymbol_ebf2aa16-a1fe-4f82-9f6b-b9515092c39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6df0acd5-5853-49e5-9ab7-193004707fae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_SecurityExchangeName_6df0acd5-5853-49e5-9ab7-193004707fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0bca602b-0853-4827-b1f0-660fcb7b8ea9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_EntityEmergingGrowthCompany_0bca602b-0853-4827-b1f0-660fcb7b8ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a45726d4-a41a-414e-b1a8-5d97d3923229" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_EntityCentralIndexKey_a45726d4-a41a-414e-b1a8-5d97d3923229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8a445aa0-7b49-4424-a7fa-e25490fb1cf8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_124002bd-614b-47e7-9769-bacacee40d15" xlink:to="loc_dei_AmendmentFlag_8a445aa0-7b49-4424-a7fa-e25490fb1cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "G 5H# 2(  A$! Q$!_\0
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MWT/V6WF7]W>:A/';1;O[I$C"0'_@'>N:NM2U+S3IUMMTU+@EFTW1[<M>3;E
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M.M ",P49)K*%U?>(6_XETIM]/_Y_%/SW _Z9^B'^_P!2,[1@J]-"MXK?>_\
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M$<>8@ &22!N &,LB\XS1JD$MRL&OZ,5DFA7*!&!6>%B"R<G&2 "IR,,!SM+
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M%OF89Z$,,_,JC6KF:.Z,K[A1112*"BBB@ HHHH **** "BBB@ HHHH ****
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M6>25+CHH"K,KG)PK' KL/!WC?PM\0?#T/BCP=K$=]8W&=DT8*E6!PR,K ,C
M\%6 8'@@5K5Y9K]G!\'OCMH_B;2[J.UT/Q]>/INNV<UVL<*ZMY1DM;I$*G][
M*L,D#A64.S0DAF')'DQ":M:5KJVSMNFN]MK6[6UN$_:8.2ES.4&TFGJU=V33
MW:N];WTUOI9^60^$] \.>)--N/'7BW2]%\4>'8M&@^RW@W7NK20:M=7%[<VQ
M>!IY_MD<I91;,6DDE:&09!6N<U']D7]KWQ)J$_B+P3\4E\-Z-?S-<Z3X=F\0
M7\#Z7:N=T5JT<<92,QH5C*J2JE< D 5]DX4\XHKJCFU:FVX15WO=)KY*W^9Y
MTN'<+62C5DVEM9M/YN[O\DEY'S%_P1OT;5O#G_!.7X?^'/$&BW6G:CI]SKEK
MJ5C?1LDT%S'K=\DJ.K ,C!U;*D94\'I7T[7S+X6\7:/^Q!^TGXD^'?Q-UIM-
M^'/Q8\03>(? _B35))/L>F^(;@%]2T::XDF9(//=#>VRE84=YKN-2[JJGZ:K
MS&>]'X;!7CO[;FNZ'I/PO\,:?JNK6MO<:I\8/ UMID-Q.J/=3CQ/ILQBC!Y=
MQ%%+(57)V1NW121[$3@9-?&?[6WB"?\ :@\<^"/%W@C4(KGX;_"WXL^$+J'7
M[&\C>+7?$T_B/3K'R8?W3>9;V=I<WBR2)(%:XNDC&6M9E @F_=/9?#.J^'8?
M^"AGC;0[J\MUU:X^#/A>>QMVD'G/;QZMX@6=E'4JKRVX8C@%TSU%>SU\[_MF
MV.N?!+X@>$_V\O!^A1WD/@>QNM'^)=C9Z>K7E]X5NY(7EF218GD<V,\,=X(O
ME#1BZ =-YW>]>&?$_AOQIX?L_%G@_7[+5=+U"W6>PU+3;I)[>YB8962.1"5=
M2.0P)!%'F$>J+U%%>6?M7?M')\ ?!-OIWA'16\0?$+Q4\NG?#?P9:H))]9U+
M9D%EWIY=I#D2W$[.B0Q!B6#%%9%7L>=_\$T]&\1Z98?'2_UFSN(K/4OVEO&%
MSHC3R;EDMEN8X7:/DX7[1%<#''S!CCG-=W\9/V/_ -G_ .(?BR3XL7OAO4/#
M_BZ\A73[GQAX)\07FAZG<12O;H%GGL98FN@OD0;%G\Q4\I=H R#Q?B6W\??\
M$^_V+/"MUX4U&/Q%#X-U6PN_BIJNJ6-]J5WJ%A<WOF:[J<(27S1.)+B>]+2&
M1$C23*D 8]TN]9T#Q;X+L_%GAW7;.^TFZ2TU*TU.RN%F@N+4/'.LL<B$JZ,@
MW*P)!!!!YJE\5S.7\-I]CPWQ#^SU^TKX&2Z_X5Q^VWKVIVVF^%U@O=/^)?A+
M3=7COH1'<(@:6QCT^Y$JXW>:TTA9B2X>KW@/]I;XA/\ &CPW^S9^TWX!T_PG
MXYN&:^T6\T/5)+S1/%MK%ITANI+&:6**1)8)F'F6<J^9&ACD5ID)D'KVOV,^
MHW?B"RMU^>X\/0Q19_O$W0_J*\A_:H\2--^TI\ ?!/A_S)M4M_&&I>(=0$%L
M\@LM'M]&O;2XN9G *PQ>9?V\0+E0[RJJ[CP-.J7];(Q:LF_-?^E,]$^-_P"S
M_P#"']HO34\$_&OX?:3XDT46=P#8ZI;AV@FD"HL\+\/!,J>:JS1E9$W':P->
M?:1^R+XF\-^(_%C_  A_;"^*OA9M0DADAT^ZURU\16\#"W5$F)UNVO+CEU;<
MJSH&5%'R[1B_^Q[\?O%/QD;Q1X0^+3:3:?$/P-J1T?QOHND6MQ;P02K=79M;
MJ&*Y)E^S75IY%Q%(2RN'(5B48#TS1I)(?'6J,\7RW$@A\UFX'EPPNB >I\Z4
M_P# ?:EW7E_D4[-J7=_HT>-^+OC'^U;^R;I$?C+]H?3/#OQ$^']BELOB3QIX
M)T>YTW5M"@"2B?4+G2FDN5N[9&$+RO;3))&CRNMNZQG'??'O]I3PO\&O@5_P
MNCP]:1^+'U3[%;^"])TG4HA_PD=]?2)%8V]O-DJ5E>5#YBAPL>Z0*P7!Z7XO
M_$'P'\*/A9X@^)/Q1O8;?P[HFD3W>L23Q^8IMT0EEV?\M"P^4( 2Y8* 20*^
M1OBEX:U_X:_L#_LL^._B)X8^SV7PK\1>!]6\>6^KV[PRZ-:)I[6,L[Q%2_F6
MTMU'(RXW#RF) VG$&KO$]FT7]F#XU_$R:W\4?M3?M.>))KGS!/\ \(;\+M3G
M\.:)9,;>-&B%Q;LNI7>V19'\R6Y1&+@B"( *+'B+_@GC^S'XPN$N_%MMX^U2
M6-=L<FH_&+Q/.R#T!?4217MP.>:*FX^6/8^#O^"E/[!_[,WP?_87^)'Q"\!Z
M!XDM-4L=%B^SS77Q&URZB.;J$;7AN+UXI1S]UU89P<9 (^F/VS^?A+H8/_16
M/ O_ *E6E5\__P#!<;XK:=)^R+XA_9M\+0V^J>)M=TV'6]5L$NBLFCZ%8W<4
M\FI2*J,-C7$4%HBL4WO<$J6$,@'T!^V?_P DET/_ +*QX%_]2K2JKL3[NJ1Z
MR.E% Z45)H?,O[51/_#Q']E3_K_\:?\ IB-?35?,O[5?_*1']E3_ *__ !I_
MZ8C7TU3?0E?$_P"NB"O*?"'_ "?!\0O^R4^#?_3EXGKU:O*?"'_)\'Q"_P"R
M4^#?_3EXGI!+H?/?['OPE^)GQ$NOC#JOP:_;#\2^"8;;]H#QC;Z[H>F>#]$N
M85OO[2=_,$MU9R2N6MWML[G8#H,  #V0_LS_ +6./^4C_C7_ ,(+PU_\KZRT
M\1']EC]MC4M-\7ZO';^!_CQ<6]SH-Y<*L<&G>+[:WBM9+$LL 4-?VD5O)#YL
MV7FL9T1"THS]%$\50HQ/GGPC^S7^U9/X4TR:#_@HOXTA1]/A9(E\!^&R$!C&
M%!-ADX]^:HZA^RM\:=7\5QO\5OVY/%OB'0]#U#1-?O=)N?".AV\=XUAJ!OH8
MW>VLTD11+:H249202#D<5]!>#8I+?PAI4$R;6338%93V(C7BO"/CE^T)JES^
MT-#^SI\'/L.HW2V-O-\6=0FLY;B/PUH[I-Y468Y(U6^N3,)(HRS,L%O/,T3+
ML)TBN:HUY_J83M3HJ79?H1?#[P]'8?M5?#=-1TY5GC^'?C:Y3S(QNCD:_P##
M W#/*DJQ'8X8CN:]Y\(#_B4S8/\ S%+[_P!*I:\BM8KNS_;4\"Z7?R;YK/X7
M^+(9I Q.YA<>$23SUR2:]@\,QQ1:()XI@T=Q--<QR>JRRO(/T845I<TF^XL-
M'V<8Q[)K\CS'XR #X;?#7C_F=O#7_H^.O8!TKP_]J+P]JVL_ [P?X3T[69M*
MOKOQ1H=I;ZA"#YEG,TBHLHP0=R,=PP0<CJ.M>D?"GXCQ_$3P\TM_IC:9K6GR
M?9O$&B32JTMA=+PR$J2&1L;HY!PZ,K#K@;UJ;>%C-='*_EM;^O\ -'-AJT8Y
MA.G+2\8M>=D[KU6C_P"&9U%%%9OC'QAX:\ >&;SQCXPUB&PTW3X?,NKJ8G:B
M] ,#)9B2%"@%F8@ $D"N.*E)V1Z4I1A%RD[)')Z,LT_[3'B.>WOE\F'P3I$=
MQ O.9&N]192?0A0?^^Q7(F*2;]E_XIPQ1EF:\\8JJJN23]IO.,5U'P"\-ZJT
M6O\ Q=\5Z%)I^L>-=3%XUE<6WE7%I8Q((;."5=[CS!$OF/T(>9U(&VIO@#&L
MOA;7HF4$-XX\0 @]#_Q,[BO0E)4^9K7EY/O2U_$\6-.5;D3TYU4?RD]/G9K3
MN;'P6DTJ7X/>$Y-"B9+)O#=B;1'SN6+[.FT'D\XQW-=-7E7P,U^7X::A_P ,
MU>-KF5;W24<^$;ZZF5AK&DACY6U@J_OH$Q%)'M! 17&Y6)'JM<F(AR5GV>J?
M=/9GI8*JJN&CT:5FNS6Z^7XK5:,*\Q_:AN] M])\%PZS;>9<7'Q+T*/26\O=
MY=Q]K5BV?X?W*S#/OCO7IU>7Z=J\OQG^-EGK&A3LWA?P+)<8OHYT,>IZO)$8
M2J#:=T=O#),I8,N99@ "(VJL+I4Y^D=?\E\WH9XYJ5'V/6;27WZOY*[_ .#8
M]0'3I11TX%%<YW&?XJ\)>%/'GAV[\(>-_#.GZSI-_%Y5]I>JV:7%O<)_<>.0
M%7'L017CGA3]AC2OA9<FW^ W[2_Q8\#Z*MA!:6_A>Q\1VNKZ=9QQ;MOV>/6[
M6^:VX;!6)D4A5&WY167\+_C;K?P$^/GB+]FW]ICQLRP>)O%4^K?"+Q5K#-'!
MJMM?SM(=#660LGVJTGD:&.$OOD@>W\N-0NT?0^<]*>Q.DCP_Q)^P[I'Q,N6@
M^//[2'Q4\=Z/)ITUG-X7U+Q%;:3IMRDI3<9XM$M;$W7";=LS2)M=QM.:I_MH
M:SX!^$WPD^&_PTTW28=,M]:^,G@70_#.F:78K';PM!KME=B)40!8HUM[*;
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MK;M^8^BBBI- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M> "<YW%0 7#!U^8X>]X?UC[5_P 2ZYNUG;;YEK=*1BZA_P">@QQD'AL8&<'
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M97CN-$NH(X]$^(<D<:\8AOH9]Q]VE5VS^-3-KVAZ>GE7OCVWW?WKBYMU;]%
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M[JBY.T$]>23QDD!0+]%%9W;-TE'8****!A1110 4444 %%%% !1110 4444
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-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140351784266000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 19, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 19,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GOSSAMER BIO, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5461709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3013 Science Park Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">684-1300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GOSS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001728117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>goss-20230719_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="goss-20230719.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <startDate>2023-07-19</startDate>
            <endDate>2023-07-19</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001728117</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-07-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">GOSSAMER BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38796</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">47-5461709</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">3013 Science Park Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">684-1300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">GOSS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "& ]%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  A@/169KSZ6NT    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)TU!(71[6?&D(+B@> O)[&ZP^4,RTN[;V\;=+J(/X#$SOWSS
M#4RGH]0AX7,*$1-9S#>3&WR6.F[8D2A*@*R/Z%2NYX2?F_N0G*+YF0X0E?Y0
M!P3!^2TX)&44*5B 55R)K.^,ECJAHI#.>*-7?/Q,0X$9#3B@0T\9FKH!UB\3
MXVD:.K@"%AAA<OF[@&8EENJ?V-(!=DY.V:ZI<1SKL2VY>8<&WIX>7\JZE?69
ME-<X_\I6TBGBAETFO[;;^]T#ZP47;<7O*L%W@DO>2"[>%]<??E=A%XS=VW]L
M?!'L._AU%_T74$L#!!0    ( "& ]%:97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M(8#T5M<V6UM'!   ?Q   !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R5
MF&]SXC80QK^*QNUTVIDD6(;PYPK,$$*N]"X)C=/>3#M](6P!FMB23Y)#^/9=
M&6+3.;/FWL26[7WX2;MZ)&6X5?K%;#BWY"U-I!EY&VNS#ZV6B38\9>9*95S"
MFY72*;/0U.N6R31G<1&4)JW ][NME GIC8?%LX4>#U5N$R'Y0A.3IRG3NQN>
MJ.W(H][[@R>QWECWH#4>9FS-0V[_S!8:6JU2)18IET8H231?C;P)_7 3=%Q
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ (8#T5I>*NQS
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M4$L! A0#%     @ (8#T5@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  A@/169KSZ6NT    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M"  A@/16F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( "& ]%;7-EM;1P0  '\0   8
M      " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M"  A@/16GZ ;\+$"  #B#   #0              @ &)#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( "& ]%:7BKL<P    !,"   +              "
M 64/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "& ]%:JQ"(6,P$  "("   /
M              "  4X0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  A
M@/16)!Z;HJT   #X 0  &@              @ &N$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  A@/1699!YDAD!  #/ P  $P
M            @ &3$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"  #=$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="goss-20230719.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="goss-20230719.htm">goss-20230719.htm</File>
    <File>goss-20230719.xsd</File>
    <File>goss-20230719_lab.xml</File>
    <File>goss-20230719_pre.xml</File>
    <File>goss-2023x0719xexx101.htm</File>
    <File>goss-2023x0719xexx991.htm</File>
    <File>goss-2023x07x19exx41.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "goss-20230719.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "goss-20230719.htm"
     ]
    },
    "labelLink": {
     "local": [
      "goss-20230719_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "goss-20230719_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "goss-20230719.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "goss",
   "nsuri": "http://www.gossamerbio.com/20230719",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "goss-20230719.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.gossamerbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "goss-20230719.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001728117-23-000094-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001728117-23-000094-xbrl.zip
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M 6DI-HT"CXP8@!-[PCKI.NI "?6T-W;%0SQ:.!1&HGQ*&:P9>#?Q;T@9:@!
M+2PH^Z*&@;;1(@"!PU&,I;,?%(TI'XETC$<6 !>23*9H&;(9:F2P4D+6L#J=
MO[,#M$MH4EIGH+U@C2 U=!GW%9E/D7JZ-T4LEED'1RPS6XV,UQ/2D]0&#>F8
M&8G%U$33B,_,M&B1D*=.1S-RQ$)^XR<Q YQ*3X $,9[+,5>U1-DR]>>HK#V!
M!&!4X;J>WDD@(&&B)<C[N$R;IC&.A (> [BUDDPZ3^B_UT'09F)$NY-[CK3B
M(_NX^DRG0EAN4](-&:UR&P(S!< 'L2*O/.W>8Z,.RUD@A,Q6I2/U$@"L]57
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MX8&S[2,(" 7N/!78-&M'^C;M1:#6<'9'%Q^7""*5G.<P<V;,&HR,S1&OHHN
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M;VKLCL561Y&W@O]-DUEP\O]02P,$%     @ (8#T5K_8.=]K @  >0<  !$
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MSVRNIE2P4!"EYZ0HI! G 8%<QE+/7V$21M0+F4BFY=,]/549_':Y'KX:8_<
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M$Z)'0UI;BICZQ&SGM5Y$WSP_!.]A[^B0G+I+6T$<73W[+U0 BR:;D[0?ZLX
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MUMJL2S&Q8-0(JAEF.A4]YN"D3J>1K1N"V]NK12%JNUB(,D9(K[6RS>,$%C>
MMX_-Z,R@]F,'>Z_4@K#OTNO1.%>55 >NJ.<1F<<+E6AN7LMTRC/X;9I(V-%K
M#XAWW;#K_%"OL:^KZ.7!80S_.<+_O,#_O,+_O,;_O&$/XB5:X)QGW[@4;@7N
M]R[WA_^/YOP/6 M/:*UU:*TG6^K)EGJRI3;:4H^.K.E3)_Y&8<ZE+A%3+IU_
MB<<<E2WS]P\J>?A4F1!/);^T7CJ#STT+$V%E]Q[$_7*]Y[1206N<6XY!HI!$
M%Q=[&Z994VK+%N^"6^!8ZR1<0SEV+?5P2,CM#0O\')?W3UOMA2^]=$NA<(_;
M/X1=^0A9T08S"4/EH6O:DK9[97,T=JMM_?)!;>LG7?> *;0>7.#@'==)!X>J
MW8=&LE8"674-95T=I<M^N&->-7",J<N]*#4_Q MJ\LR0RYZXSG\CQLG908X!
MP6+:L80PXAA6H)2UX-FG275+@KE)6$LLKI V%WO'^U1 A.L"]W'FA]>+L0?7
MCHUHWN[CY3-X&/T2BS7H4N0Q6#0+L)6PH(1ZROD]W&PA;GOLL"?BH.5R7[%M
M=R]Z#=\]TDV*?A5ES;OO;584BXDNY]'[@XN##;L5GBDUD3$39?#K+$N""O7]
M5E?H$J;5-3=?]D;$7>1QM!+#\4=%24#8"+?I5')\^89%5=%$Y3?XW0)#9D69
MPL#<.!(]S53I#ER0VHUI#_ZS*&_X WS@"0:4BC)/E2VR[':R7Z=9CQZ49GUD
M!N._G*X:\-MF:6;<IQY1I:+WV&>>H=S'"7MF6-> S W5/1+7.WII$#6,>4!I
M3#7/!CN1N?<B]4HO9-&# IN0CP^B#T544!85[],VR4N55DYNM&:PSRCO ] $
M; M8HHIL$:HV]_6Q$(]6Q&QYS*SE/L8=UQ=+?BPB\U\Y,>B?>@'?,[%C&Y*/
M\>U6IF;42<)HQU!\(Q0]P/:_D'Q["D[\8<+K,08(^Z13,:D540"8<@C\!DT.
M;F2\1(0EM0U>(LQ3(1$&M@NKZC)(.J,LJZ)<@]]6(=6A,9SZC)=M"OR,:=7W
M>\F";V\"^9UW\ 9>/1J^M --^V\6E3AY%6.BN?^K,AVCM?E21N2DD6OC&IM"
MK%8F'23\K(%_MM$ />'5351XR'OWS>9"]1TC/Z</&OGIA<7'A_WL@R*%P,\0
MIKP!_HEL<1Y4^@D-^H0&?4(P/!E.3VC0-=+BJNF%WS\>0.BK1P8(_>JHS-]G
M?HZV<X=WN3CKB:/#$^!A;%=P*7Y592NL9E,WE4RI0BHTV()@>C#<U=+M":?M
M^KM^R2[AI<0;^T]^?.#4)^/ER7AY,EY^=_AEG_7"KS-&61&:+B.$9V)#Y=\!
ME?GE0GU,+!TOQLS2<6H)AYZ8,G;-E#% HJY67"D?1C"YK0*:SR-@*SN(CNOP
MT+=(%EAD22HMYN[KV.J$A8M-O,6M0!X"H"+%S W4O0&_K_H=.34'D8:,&YTI
M\M-VQ6C3=M-KG31@^1WO-&N'TI_9ESJD&%MP7[1#G$^U5U_$E#T:P\-PF?C\
M'[0OTKP"YVW:904<^^EZ.W(.""8Y83Z;MB"S?G.%K6&P"018;HBZI-82]]'?
MX_)Y'X1U$.V<&*7?/#BO\&1.=1OQ%NCC<=D&7:HG2G[Y9D&/+K&J"&0Q2R+Y
M59?2"<30G(F:"1MH^M$IHEMZAG1+*TO31(AL3JR'=6:##X9+\@:1TSCE,MTF
M4]Y/]O2 R#Q'887P#+$I$K=SGVJN4/N@D"2[N#/A Y;RGH,6, \6W0Q\V:5M
M^)&6I;XM&&$0:#B'#&O5(@[8/:TM8^\EL(:!K>R?WPYZ"I\\A1&D]B[AE>+=
MPS#-UNX#/0B:/AR ';9W/*I5A<TKY'J_T,#$"V9I*6B/F2F7Z9P4P_HI0[VC
MRC=YV\3</&%:,*JRV3^(KKP?6(U'H)9E*=9GIN=<EO"03E:0JCD8 7O'IB90
M_S*,9[O&O6RGV WEWX-1[=3Y5"3GH,??H[V5A>DSRHLNDP*['!.!)A/D-6CT
MB-.:)<-CG(ZN6)C OX+Z/!M0.'KU[RWKR:GS'O7"&!T;4%B2)]JF+[0RE4<\
M>K]H#%$'2?AB=O&S+J=,6XJJVZ[4OQT=/'^)L6A>TWB@?6;-H@U[[EZ<OK,J
MOH7O<VR8+5W;I_5D;$69SE.LE#%;M&<[N_O@3Q!%B$IY[]5^0%C*^W'+;IFV
M;^ZX!6DR2D$*FA=VERJ=>7;B.%/')SX]:\U+])1ZJA%_AQ:K&WU4P4X(BHGY
M35O,J(8E=F5,1Y!Q&#/S6\"^+;#!+/QQ*HUMJ]9-*(\3)=A/0NHB_T=3RFF1
MUK6V%IS@C_E)G5ZQ7LN#85BP1>8^EG.A1WDN3BB+1R;&8ST0%[#1L3DR;[Z3
MZU3/HK//>MJ0G_21>SFW][E_5CIHVD?4%&6G/<W7,?,_K,,]&^7A_KA,<UCL
M@YWBSK[D-.=@4=/0US<@P0A'I3-;ON)ZO)(*454+3"A&'&(B."C(1/5J@M@V
MTP6I*%<;R]8>[#Z=CW*?O@=/[!FX;-9,V'&AQA=L64T*!;N%R[LX;$UW.WJ,
M,C&W?D@PP2UV6;O;36)M,8*]6LW%/7HZ)II7R50LB%I#^GV/W_\\&87_*5$&
M$A"JKA6.SJ3$5372.3S[3)T]=IO:'#%+T2FICX^1B)HQ4!5MIU->_P'*8GV[
MT)>#[4(OSRXNSZ[./GPZIA:A<?3+\>7E\8=/YV?2+O3C/\X^P-]7T<=WT:<?
MS^"#GRZ./_QSJS??HE1RIYB^,\;38UMN[OSM I0P<]%I,6T86MGMW!T2.+FJ
MAXZG7.1,V42J( #NNV?:.)>O._"SR<KA[T$)W=G0,:5N;I& JN[+,>'W%]B2
MC89Q/&=\:"6%@55_\=\7FD,[7<&7X^ST^K&<JSS]'TZKX6)<U?#?G4?Y_8IT
MB]6E2%":@T9:HE)B9'#!+R!X9-C4M[ !D@PK2828AS[/HWE1( 2?WRXB;<;\
M/>J.K)I3#?]""\9TL0K[7R$<S3Y:ZDL*;_)B&B>5;]L!NELMBSN)XQN&KY57
M$0_'HKBC.V8:$PK84PBSCQ@6T XNW6"]"GPU,4%=A9?1D8/WE2L0TB@S0?/E
MZ.KQ:*.A 3.=1_Z;]$Z08+G].:A<U0T%)*Y5B5W(;#A#AKS"EQ$&-TTI#?&8
M<E4C"%NNMF]APG(<1$EK:2HF Q?*)3M9<22U17?$:DK&DT-W3RC;Z][YCHKS
M$;'D>5\3%&R8NN;H.=G6:H@,-=R+\&9H8I.1G*WXQ1CJ4363*DU2A<#FV(\Z
MFM1S4]NY1: [5B6Y:FNO+!I7V+^90+A"N]L&EOTK_ZB3@B-\.AN#9^,)@OI%
M$-3-RGQ'FOM?2-8]$DMKG%UJK>2[0(''_1&/):^E1M%O-#"YN(4+:"K"&CBY
MW2.N8QL^\L-)*(Y[<GRT!6O8]OG@(SA'1SA+F_B+3=2+[FU 'CUNC(]<H5M8
MGB"]118PS<U-V,_QV($*:>?H>%/<* +JE(Z7$QN?:@KC6J$IP*VHN<+--Q:&
M&5L\^B W0LY9PM+U]]-LI4YC%SCT1M^%&(I.A6-=-]B-E'0_-GB-V62@"R8I
MZT*/4Z8=&I0NM 1N-!A*_SDXUU-8]80R@EQ!B$ZB+A>5%7U[J421X:6$$)BB
MF%X[6Y7?E,VRGJYPN4 O@K>)_RYU:(-X9+U(Y0OWRE3)1@UK8%YD3#J3-#2I
M:WD-DXMC2"3L9%DDP_?DT1[#].RE_>,FTX^&#6YY/DV7F<^8[.\WPBIS1]>I
MV2HX48]%2(^R2-%"X' -I5+18AO<$=^]I!;8F,<ZW8))$(\WV VY<4!(XB S
M!2:PTEQ*:MW1$ZOF-JT<2"-D2B-X'1@4QF_@&\=DV*_XWEP?DJNJ0@L&MCF/
MUB()A\?;(X-H]-N)K&!H@7SRRHZ_@GR"K].R):%4U1$3!IFR4&2!>>?_RX05
M.TK;BRP123@/2/>>B(MI11<53J^,W.D52@<1K5SJ'XBD?2 $YEBZ!4ZY2[>'
MDEOB_"_1OXGY?$^+9\CL)W_14*F!<UI6:+K.FHI;B9._';QXR*Q7(:;RNLB2
M;EHJ_/D%7,!.*7Z6I9K[^L'$-XM)B6]7!?WS_"_$_?74C>>UXT($&WRK8XE8
M*%W>2@MS?X*[!]9M^&8)K\#;VV(5VSC=<,/2)L1=^V4G-[;%7O\ZBVF\-S.C
M!]$QS-3"'"N%O>?5U.[_-I,340%-5BWK[R&!=';*Z,19A6(V$Q/7'HUV.ZX.
M)2A('3@4L#&Y,B3@ZG3Q*^\'QU/:IH=O7KR@:BFUX/*.\>84P\$_G)3B^ W1
MEV,T1(.L'L<*WJ78Q06C-M0YQ/OF'.:1VJ9@"HU+L=3.<2U^/$&L A#'<K;@
M>M@.*96]H2XJ95,%^4M09Y>(U'CY_!5:IHLFFY.?/G2B]SL/;7&4<ML7E.9]
MG7"\F]FF2$Y.O'P@<L(?^ABD!)L1%/^G!B'(QM.4>5H1,0\9)OB%_SE!YK#W
M4(8-EO,<U0%%BG#U0+M7 N&!?Z)3C)_8 \&9;%+_B4V*4UE@X"XH4O5I%9 .
MT3BL+^1U7^(-)[V:^C0)?^I/?2R-\B:@<\E^Z&S%[@8,=MV>P(+TO*"> "[#
M7Q=S32.1VI65]R7/<4M?#FO LC5F,#_ISO %QY%Y<F01TYR35$2YYP4J8&TT
M(X)X^NWZL F*43PT9>T@@\04 0= XVMKLJ8FZ^(_(%#IK>4&V4"5J V8KNTV
M-&X5XVC2U.BS>?&5-*>HBFGJXB4W_4BHQ=U1#2I*613"-3;Q(F_/5J,&#]/,
M:IQE7".;R7O*7C,ORK[C*"5)H()&(DI\VG3,U3M6F")O+8&-H9Z=_G!\*>7%
M:-#+<0,_WJM@AFU#T4PKA>C08<<N[A*?SJSLWP)/(XZ<_$(&W@+JA)$^!?^4
M/&V3FS]F5N.W=CS^ @ZH=\(PHFF/'=_:P77V'7_:($6;/3$;5..@O).M3,*!
MXQXN+5#2L-CWG3>9"NJ /$'K:WD_P/VAR!W=1#"-ZM[+B2%_U]8 3"6D!+7S
M&U'41B8'$=H4?J&"(SJW="&HI_":%G4=761GGZ2IG\_&G)\XO795R77TL@[@
MV8HK39.:EO#"F']V7JR552NN<L<[Q"2V838S3;VCR"#"8P+_GQ=NT#X8@78<
ME6?=2G65"&GS[RC3\/;@QUHY![^=S<S83E,.&7*UJ\N<L[FJ>U:YW<D*UR%8
MU=".6VA=5]VM:7#X#0="WF$FY>K9BT%MQS?M/5)[80^(X&3MMZ,1 ?=0=T..
MUS+L\Q_&(-99.*TVB"8O:"-L$QT[GF+&1HP]H3 >%PICV9C>GMLJDU#,\&EF
M(=!W$KR8[1(\#244 .T$P _'QQ>4',4R!\(6T<:$BQ.0-2) EO"*18(R]):E
M*@YVIM(2@ZT<,60PAQV'V5)M8>-QE5<VJV"UJJZ:K+:0+ 2D>)3RH(BOHQF"
M:*VH-..J*;'"CJSX);82@?0WW-%9(4Y04CH]1XL9T^ +[Z2"H*6W=R7Q%7CC
M#K7<$9J]2\"V>]>^,M4K;<,<E1V([H:,:@X'JPEH_IHP>*CH84RDU"6%<I=6
MVN9M:NH*:W\O X/5AJ&5B!EK2IX*@]Z)O86G0 7J+J:*I% Y07[V>9\L%1(&
M(6:(^]6&7=,-GT3?+* .9VN'-#PN#)S/-&DHM\RY.PI&&_;)F+<N$M*C"T,H
MH-^&=E0NAH2%/:;<5=K4]2Z=(HH^%X:BXSH-[J0\;[O;BQKM2K.Q T?8[79W
MV.L.%B*ZX >:[7'L=,1'?$&RI@B-\EC"EJ_&&+8\44NR1\8":/)Y WAHG&GJ
M5&#SP299"F\6/^?_'R)RP4WW;=]52^OCTV/(W=Q@,+8J]=S5UAM8AP_R#'DW
MBO!5UR<CPY0@>Y>EWI 9=+>4G_7@"7#4,YU8VDCVG%H)-W81R7\A86[O=IL6
MF445H7/KT:[D*R\/&4G.T23)36NV@J#1TS*=4!@-+["$/6X0OHY:7UD3\WH8
M5\IBIHNE-*VZLYBS*;QZ%9OG+\4^"0<8!S6;]-.Y\;E+X;BP+CCM4(- C8/4
M?^TAS-&1DW^OV^RQQ6RU:D ]@D.A58L%\@8;&L8:VQG$3^QL^LH5!#Y)^#;[
MDDDXFQL3\S(8SXFY-_YM.9#\VR>]]V=UWWK+,KHM:FZ@.D'7.7:3+HC[-$=N
MIPJMAM":P!WFH?'M-@*Y0)S]S,_'<18MVHG)B&EO,LF/8"%:S^*E]W!\+=$#
M-YWCQHFYVBKA;'9-I)*RV^D!O-'L/N-M%NZRUB;S]EBPQ<(=)@5W'[SPMI3]
M&G,T !?F8DNF'EE8(!L=7,5-J,_FR\>W<$&#U@-:*7A.$<SYI/-^ZA, _J)U
M\0<Y[,%KE<W,87(@ K:AS8FOX0YS74H[;\8AU>FS),V:<'Y;( 8_F&<^2S!>
MG4X:+PF--Y30P+)(<01+>#F3^EIF*O>1B=Z*@2W]T4$:C)]CIKPEFF2$5ALX
M[,0T R'.>[U,^U1%:VLZP>+IF?[6@AZ?"][EW"\'"3)GTB8)<PG<4\GG9!0'
M9[PQE'6O.8982@>);1?H[4KT[6-9"GZAD4QZJ5W0O=]Z:"/DF=>!LN(+D?I.
MRRV*!+P-OG[-CL,?\32$3K,A>?M2XT;4J&^A3)K5,VH3ZG]86*W3 GZY-KX>
M^M+(SA"1B7-QDPYR4GAX']$GX/KWP\3:9E%87A?$#G1F7-#%8W$'OQFC._@>
MIG^^<^'8RH)(*<.\ ,LNQWW("$6)+Q3$U"TV?=50@^L4C,#*O D:^*!;YQ1B
MRE2ZH+@0UI"D?- Q;$8_0DM5S$FI="R+J=:H1.' :I-^L2U(_BLO[C*=S'7'
M8*^O,=FL*6G5 U0V ,EN\6AL^B,QX)==W::L8_]U)T7"]T@6:2Y9=@P2S1&:
M'*(O@TES%^ =XB@I%CA-4TJ[<2UE;'*UP8R2,^;F8IL0UW1#6,NVTIFB7-48
M/.K:E?!,)BZ!?R<@+59B]&TH"(*K+17_IO"9;T:;Y<G7K4^*E:=+A:6$DL8-
M@2(A))]!"[\VN51(_=HD<[;O$V1B9&<,&_A9M[%WM>/AM=ZXSHRF69# W[)T
MVD3D;<S6Q!I6:'<NS8C-P_G/JJG,&2&?A 'NMYKJ*.7M^E$A]T?!M(..7:7P
M$-M7[%@C?3M&C?2#O[%/X%3M.@N*X 8*/[*73E2FJ)[LF5!^B:B):O@;/P[+
MAU$4(">E_0.4E#,7!1C!90%X+"1$)Q@ZNGE63&%R0A%@*_/EM'PJ"6  1[^\
MT=9S0#G6=2)=V)_"A'G.B'.7J[45FEX&;%@JT[D.1+LD=$R:RX _0$8P+.!T
M#:IO( W15QWE&914890A<.1FQ94#HK)H%GT4X@!)P%!@N10 /+O='"&31K?^
MB+B<@V5B5]3UY"TIA$3U*D^)\=\I,3XFV?MZC+(7!-VIGBF,M\'>'HGP_0)[
M+4Q/H"G)+\4"A>U;5\L'TC-QP*;>,&OL5=:5?JWO%N'1UM$WX=FV2/7\Z/7V
M[L2(>/IG"QEE@KZ@+536J@G<5*2S3V*+"+U<47<8UY4P EJ^NH2C*S0Q(,MT
MIDM3P)\T+HM.H6!IRX.?TQ)P6Z<BGV4@=@V+?BO2:WK#\BWP<>(@V+BTN8N4
MP2,3N:SS'NV/2-_B4UDXTT/ M,7> :A!L6,V34&Z8-\+E(&DYOMNN>\-7)1E
M9-*2LNAWBJ@&_.O\]_%"]K %%SZ>Q-3)&;^U52['E842E3>T.OB&5:4[1;/&
M&[1G8A7$]FE[87$LS1^K(A2'#79.6!1E/0>AC;M=$RE$78+D[ D,L0N('8P6
MTJVH"\P>/J.^2\5N+_]:3A[O[H5W@[J-'@TGPL _-*,<)D6#E9KR\QG.X37!
M2F"WZ1S_L<3-6W>=,S'JV-1JT-A"*),7>\ %\T[<QNQI&P2UOQYPB\%?KYH1
M# 3DY##^%&,LPH)&2LZRI,%G#M0WFCRU[+5*9[-GGL/I"\-[KR6O5AIDDW 5
MQ$O>]W&![4ZNZ+=;&@:6V+HK&GKR49NCKGB-B:B+]=G"3X'5C>E/G[YB&X(>
M2IK&9J]NCHL,.M\<<?8L8[( 1:!43J)4LA[LRF<PLF3%J?UB8G'2B42XF<.+
MZMSY]MO1!HF!2';3P[*CWHS4CNHL^@G%+G9K2UT1R.U43S7V01+6_\,X.GI^
M=.2S)1A6$]K5&_A,VT5CN!UKXMI"I]/YH:=J%>9 SDR\2'C8]]1^!S]H:>%"
MZC@B0AV  Q*WRV1?\B4.!X.0D%O)BDP)44A0?;(.;W56++U*M/O"];Z&.+"Y
M(.,DW\._CNW;Q19AN6J]&LVGO#E#&#X3GJJ-];^OV/>TLM/#L:>A8Q_W2@$.
M@T[T&F;0M/-43W34JM9P.[ W8KB&+4#0N>%6,VO,H4X&%!,V,=CL7[*)S0G[
M28'JC>1DO?B*)VOM 3([WKV7V/)JGY;1HH$3M1 KS_:SY*@2(FA;%89(#2QX
M4##XFI*="\%X& NT# RR?FZ([A[BTF@\JP*?RMGTI72KL2L]3Z4#K5MS9R9^
M&O+R:/>* R,O;R>G\W0\>J74&?D8'6NVMF)I9'Y&O$R26W&C[)TQSUSB<]4J
MADW%&MBR&-:W]\^Q8^<WSP]AEO<.GU.IS*4S9:^>_9<LPK2U13(U0?&18E,!
M<&+XQ&^1!^/?-=RL@V>?$M6X3_E<MN4-2K5BI3L;AP>&%F+">@&WI\LTE[<$
MVQ:+MM,&8;!,?; TO?7XQY)U/GP^4@/I!Z$VNBI \J;U"'+0/9&FN!UJ.IYA
M[!HCR.XKP:HI9G>"?TD"E?4CX]J88%?GZ%YSV0JZIACZAAL;EJ?*FPJ\@?E<
M)01QI)XU>]) $ >YT'"^.([N'>K3[:@8AD+]S.Z"[@@&D#I!HD=S+D9)]@[G
MXAP,O3E7WG_$I?![0>XNP_E[G@T\&B%E-YK1_%?,(0U^RDPS,1KNS,H%,P1T
MQ-D8/$ Z\7^ -F2S"JZ-Y5B$5;N>#6I"?$'ZNO=T]-,=K4MEFW;VJ-5E@7ON
M(*ALMQFX:(GL/_.S3FP970?0_LNB<NJT.P"RW#R;V1%[V>RF!VKP&2_=:ZTM
M\0M3CT^I^J\AKD;)F'RERHD"C^_9Q\^97NV:T*9#+@0:SAJT?>GB7B*%SBOA
M-T?/GQ^Q?$!;W2)=./ V%-\<:O&UGG/!5][N>!O;OG9U=5]G.(]&GX^3K1;D
M-_'+8+/J"V&D/]@UV>"?_OYI,YZQ2Q4>QG_N\AB+HBLJNY7,"FH7;H1G:[PH
M6(X;EY).'==VHK-4WUI]9\-LFHOJGJ 0CXPC #&R&(+E?QAA)<DO,+02#6._
M\?_=ND8\_\B_+,K5@NO)ERM3O"<[TEY241_L2FA0;V#C/[LN[B3S8[% K:HA
M*V(=.XP?*D)SJZ$*]5Y/RDM+MDD#^DX4!2RX'G*H=9A/5L5G=)2%'[U2+[JD
M.1U#.4A/0=T6R)*0:4Q%=R5R#N4&5&!%V[JWQ^W2B6)W,_:2"F4*O'R&MCXZ
M%4MQ0EP5G7.QY)TV"G:4JI1H7#M,,BM\\FW3SX")(EUQK1F=B8BJ/"0!#ARD
M=8\,C;?> ^+UI7!ZPOE_"_BL*5F5@!%5"ZD(G_RI;9I@^>'(9]P\L&@O9*03
M$48AW*X0\_)'16E@@&![:DDQ[*_O&),4V#'&IJ&WP=W_!B*);?:*BPB+0'5H
M$!<R=_5"+>8KWQJG&EIDA[&V0>I/N^W7LRZ1W=F(+J<AT!^IH9!R#D;M&V:9
M3@<5N %/'YL?9(JX@\QOC&3L_%:,T#33X)2&]_I)04D3GGG$7J6)]T'03*6O
MJ9:I-/9/N1CQ_5N4G/VRMIDR,\>"#H-7?BSF_2@Y@$\Y@0>'=P0A.G]STX:E
M>N#*R;W  /?0022E2N2_-/HE!!G%/L(H;!?:8LY(Q]H/.:!0?[G3ILBVF->@
MO.Z1YS^(CF&I"%Z9PDDE1E8C =$VF:O2(D';JM3UW9/PPT:4:1M:ZE&Q^D2I
MZ6@;B8M!_NK@]<X[B1>S_=C+XS.&-V ]\->LVX77V'XIPT^1(4,A9)-83-DF
M"EF'.]X#.D+2%4MPA<-\?LP&+/E_(N.\'Q7G, ^G<Z2H;(_B6+^=;]/O>KJ)
M;'-01I(:%PE)T&,[_3%'$F_(X$4MKZ>,1<3TM2,"Z6EU9LNL\6<N$A^',I<,
MBZ%332U_0^Y- 0KU(7?L;'.\Q33?3(/X_+V01?Z^#-5(;D!/M7.;?.,_3/JX
M7 \G%Q(=U(Y[>]VFA]3<T>TT8'1E#@_J"R,:3%J[6)+?&FT+!)>']S;31Q1O
MSX0BK?,L6CS<6HX/($ IB9'NK .[>#W=OQ]- ':<=&<%@W>VRUMOT63^Y>N#
M-[N;9EM$W?TO]2#VP/P&MA1SW]-!=#\)2>T3$66%\HATAC#_5+SGNJ[R(:PZ
MT#T;T2* \P(FFXC->N-;C)F::$&^4:=[0UQO!%SX"Y>0[&<DW)AA\?(I#R6Z
M9OUYN[?'$%.C9AZ%6^_87VTN:]5?C]EQQZ=P,G@*T<#H+M!O*9!IDP-ZC(#W
M;QQJJ@R\6&/82Y0#'T.M1 =;]?7<..S>-Q&RF!YNC-Y8WV!G/P]NW&GR1R.P
M3V40=+?!W[T;DSI9.-C?[[X=2#D)O*Z[7X<L1QHII"9N:=H&^A/@A]82O<@%
M%D.JP!"==2?$5#'A&O85,=V[!A._VP(K2I[.=5HF=J=7)O*==(I^J%@((Z6L
M6FQG7AR!:W!KM8]3# $]1^R;G#T']8]Z508GF!)'6Z :<P+52S.TD@S(==SS
MHR#*WO=6&T.]IGX@K!) I1YO53H9=VLGZ32J[G@[7(.= 0\D2'JK?;>>_IZ(
M,)W"N(V+Z%3TQM;3^:),47<)*>AO&P?AOC9]&X@269>6;:9_>O:V?^F9J2IS
M]_T/'ZFW[T6-P-C"B#POS%/F_7%EWFV]-M*2@DXE A-#8S>PS4PI"!KBIIK9
MF/TY[SA2+45F520ZPX_'I1TE9=N%5S@"1L0Q592,+/\PG+^=%P7;E L"AS).
M+:T9K8;12-'9_BM*T8SS)17ACZQYNS#N)"7-ZW[^^_4DWS'(8"W14?"7F9TK
MR[A]K?.=$;E"TA;-+K]O+:LW"I[ZE(EBFEFWG3H:<*^JG.S,6<9AJ#0?[C=
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MF%6H)A8Z=GR=7H5%K3[#/>JF%/./*X%X#-0!L2 .VI)Z%F ,&:<TJJXQ5(>
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M3&26Q&#E8.WF:>LR+VA4B'[I6![1^<POZVV]M^\'XUH0\=YDU;Z]O(5IJUV
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MZ&D5N/JU^9X<"PF0&28IW]I 7-RMU$QXO)G4V3T@5L^-1<1&]YJ21IFYD'2
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M7Q$60VHGU.T!LB&"?A-JAZK5]/9I.+3>L#9\/8O:W8L0'4XSM)$^9(LR6Q9
MY^83+PKVF<_1EIT>M!@3$@' _M8,P7#>-=9V,RP6<+XAU]W49^7J(:>E[WZS
MV\\&>UP<.W# =8Q^1^96>!9P?;;'SK10N$(XJ9BG8XE[T6;K>!LNS:E4I0=;
ML*5D%@4DG"Q5X>JBPU)CTUA8@ @!!)-9U471FB#3LH"]7!/E5:'3F(?:-%4#
M_Z8-V1(O?6IJ"6=3R-#GZ#BJVB0L&/P@8*W$+?2&WO3S).[MJS]Q#SSQW"I
MV!WN0\<E[(_PJ(>(V@IM:V<*-HR_D843$6\Q9PDE%;,WJ$<VH,KT26XAL7D9
M6*]MUWF+JF: L:,U2C6FG@-++$^Q7>_US+$XYCVW<-H<Z<@MIRHZD\KQD06>
M.U\U4V$W*_P?E&L%M?^=+8RCI;"!.E0\!5WA#Q,9:;3"6$DV)MM<1M 8#E?"
MQ$'^,9N@1XZ%-"<8>O#Z<K!331,MJ79K(2,>$$3)<,1NB5+)0A]N>&U%1HG+
MK^R4SA87(W2]FA;8+F[\L2GJ,A;$SG)0_42[ D*-1!WU+08O&C!FNI6G-.?L
M J?"H>N;P65ODKJF.EU!TN!AC*.-^2;S"E7(,:J=K\Z7+;YTKS'DPD3/\'\V
M';6.KN%,QC;.>VD,0&,.QM%H-IG:R,M=6>17XX*G^L8H7Z;S>&YT9)LU6T"X
M^8OD9.B-<$-I/1_VZ02B0N!&UJ-ECCM($W-P8/Y"#$[(&+W5V"5T5\>!.1SK
M\DEX?.#(]EB-FLCA?LKPI0OGM_ILS)OO$K"ZS]1BLH-3(FX1].%R-D&&JQ&A
M/?$^)IRUB>+V4N$XR6!LF:GGV/C3BHUW2")TQ.!"JF;E;<86G 6$X273C%*@
M"][^H"L1*Q];QU_ML(@M6K9W7H:Y^+2VK5H1Y)2W:AGM D(EH3WD>8&+3+3Z
M^\+;'?GHH=2..+LISTGU@A<860&PT'DM"K=');"[Z;0G5&,ZK3L45M+@V,:A
MS"GH@W:#X E(=H3AIML7X&LPBTR2EE*%#@EW*=X0@)S+%'1Y<U84AI*O=Q-3
M( G2+K.K(N"!">HJ&50*3N:.TF],Z$=&<Z!:,<A(2'$Z_FT6?35F\*0->H?<
MEHC?,T""-PU-R5CT,>$W51ZB]D6&"HS55)X&--$""N:#8./R -B%=BGY=<_.
MBF6<%;HBT2QH\$B1C(4X3^8(-4D61FA72%JLYPWT8C!&JYI!E#QC[=_/%5\0
MC/71QF.H.T4+>>3*3Y]G=LF950'5XNM2U#4ZA]1UU(#QAX:]$JZ=NK@-TUF/
M,6?UX)E$B5N$]]SI_@HB2]^H(\Y/)CQLB#9(!PH<B)5'%(H.D\N)D!Z)\DH6
MS@/\__IL-&^Y U#NI%+Y])9=$39EC4.#)_TX51RKSF'$D1K@0 H%H1E1X9C,
M-,>D#=YIM4O-):,;/FQ0X(&4+]P<'1_CI:-1$E:V]PZ-_7^9U8V*3!E15Z>#
MUF#S/ITGIA\@J>5Y:B12/FZI@+27X(Q8-<JKJL\DU>PF#08I7.3--+4@[[3!
MF^>,/7%H^IEKCNT^?##60D&(Z $L]D@,8158B0.!<Q8^KR7*TGO;R'5 6?*"
M@CSSP<3@0FB9S*^;,-D"_*X%"9'H."+/5#))@YWBR:YOL#NT8JQ0+P OZJ8
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M[AS' T<,24FK_6>7_B@^2I;E52]YT+"4@@(4%Q,L^#+K+#*-3[0%M0''I.3
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M23[QJ\(T@1X.F;WE%%!GY#J%LVZ?4Y=F;J#HP^-Y*,JK),_^8U'+N>*/O,,
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MR-86!U#:4AC?IF<:+726(!HC;EVLG"-JAK;"P.;.=D77HCY"I>K<Y2/J2I]
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M832Z%NP'*3V42D;?\!><DQS3\XO)K3-\+],Q<EQ 4KT1%4@63$,B'8SM7Q$
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M9K'YV<>]Z#<=M!>G'Q.OJKB>PJS)-+R8!;.P]0T5I\+,:?9OTO(*6@Q-*";
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MZ9KIEUA_@@J"%Y"KFTRK]"?YXV=@F9DD\Y^R'-^+-_U\DY171D-AI<M,W,^
M1 DI1ZQ]XNZBGUEW>;G5V]EY">I+;414/987LV;30\WFG_6XY;>7O;>[KSM_
MWNIM?]5OV[W=O=VOO+.[L6_-8]\LUZ!_XD!8O5!FE+9!#='>264,M__^V^[?
M@IG\:2O:QJOD'=_A4FS=/W&ZE]&/_[RZHM7=[Z+W_S@C:6MY(PG ZOOG%Z=
MP/$1J4847<K)Q>G^I_[9P#&N++:>>%O6Q?2G[9U[AGT]C>MGT^1QF";?40YX
MI]7NZY4I!;+Y3A]@M:CF?ETGU_^N;S<-.P^Q%"+Z[W_O_V_M>W2_!@T3XW32
MJ/NZ;SOEOE:'O?GN#_K1@]\?CS'A&(+81S9K1R?,?"^K=)GV+;9*NQ>+GHU5
MC.J/C9]^MY%\Y.OYO2+M5=A#L#CT&H\V,JI*0(";A"Y(U',HFVUSH4'\.&=V
M%3,D^W/]VO9-]\BZ;(B0I&'A.?L]AGYO.;5&@- GT?$=(PM&[R;%Z$L*?!-[
MKW=W?XY>]O;V_HL(*.B+O?"+[<8EVWC-7_J,'QA[[F@&%6A/4(0]<:/@(0[/
M)0;IV?'T.!U/RX?8WZP^Q.Z+PK=KFZO1YOQ:)(J8SCGJ/[@/CZ'GO ^PR-TH
MS*PW+)6>\A1$Q7)'Z>[N]]Z_VUNKW\"/>1DOLX'?/42+^[K!>,"#?O0V/S1*
M]8N+J?.8/\9.?"PJ,-?+Z%U6Q-%!/NI.+/F*7@R3T1? $,_'+[A#E_C?SS]*
MH?L%8A7;>W&TL[73%#G=/7NXUOKR-82_?[XGY_(%7;8B]?8P-??E7Z(31FN.
M#@_WGT[OMG>WMJ/^;9K/+(A+WZSL;)14<;2]\UW,LC<]B*O?;Y@U#W70:5_L
M]MZV)#E *C8)VOIZI>48'R9%T<Q%>;0+1,".8D?9;G[8WOM^/7QB\N,DFYJ3
MXBS)QQ/T)NV^_3G:+Y9,17P,'7R[M14=90@L6$>?$3/K;);5:;2WM?5T>ODY
MR_,TF1:3S A&_% 5=1*]>O5R:^=Y+RPYB)]Z^SUCW&7Y'96RV]T0/ZU3]>7N
M%N@+7_ADC:/O0X'XG0_2<OQ\D'[O@W1G9<+COIC!8QC34T[*6,_4]::9&+V(
MOI4!O%HHT,-D+&R^'X'6"7JR.#5KJ=YX2VN%(8WS:V%Z-(T32BW&?L)2ZGDQ
M0SB<J067XF+7-4:Q#G"PU@-/&8#S$7X16=_&,R & U296X"Z<*/K@]*8"0#&
MM83(HB6U0G(J5#:FP,$BL4W+=ES?V>(ZX768)%O:KMB3 ,N2 4&R/$94VS'G
ML'K>HS4>X>9R68?!CAD@2ICF$' FF3!8B8+;!3"'"M,JNI!= 8VR,#ND-B>.
M0QQD+O;*XX]<_D&]:#^9XAA#%C-A#F,>M$<"62L$7*$E)%P63)U6<.A5"%"0
MMNSCKW6OKMFI<D 08QD@F0J,)$+UY'4Y=V #S?X3<(&YFO!IKH!<#+Y!= &H
M&_(?2S"EHS2;ULPD# 52&4&07C)B:%99P&R'&3*.&?/('7T>U,]X5@K:S=2,
M@6G&,#7C3[CV>0/@FF$2ZRR?X6V%0'TRI$_L[MC;(G@UARV-7P<0%$JTKZ]@
M$0WO!$=H/81*.*L*K/E^(&$S"6U.\%@CB1)D+*"1()Z'V]3#%'$&M);^N'?Q
MQC8@PUX"3-V4:8:,P3R)B?@Q86Y5_ ;^)<"4J0",ZHM$_,9.$'=?3$]$V"QU
M52R8@*4(=O_!FDR6$%<N"7,:*@F).%$ 5R=S@IZ63X3T]X CAL%A%#R::3\Z
M%X@LF8C6&0P,Q19^)(AC_"P'WJ+7.+!9([2 SHTPC1VO93+RD:/ULF^! W+X
MR?I"0'AI>VK%N%UWA-=+HTC09VLOD"@KBU(QUT,J 21E*Q [L6,Q%L]-\H4W
M!NTZ4(=D[[FEG,F)"E>*"+9YIWL_1PM\28]+_NQL:G@BW')WR=3!UR6N& W1
M_WC7$U7PW74Q88QYK&J+-=)3:C9L<9.-2/(#[.&(]GYALV+I2EI*+>O*[4YL
M%V)Q*GPP#^9)(+RW-^D)5.56, 2@_+K#OV85U]:9HP51_<SV'KL<^\X61<)8
M3(-3*30H:$-277M"$K]%#%5"(J^%DWDI[X;DW 6>M#VHM[MO2:T4> ]0]^U"
MN6^2"<IP6.0)0+(!:-@EGD#P_RI^SM>R^5HO'TFA[Y-9Q>^\5>P=#?>O:A:F
M=6FZ9541TH:T9F1D$%0+6 8(I39TK_U'/[+[FS"8M1'>,X;GGB/3-HP5D,LC
M:#Y7490@79_N4+S_!HML5)13CA@X'GASOL;1)+O)P)D&'.^$;CERU F,3PO
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M)&V&LA43)6(U58G)&2!(9S$,VT4:3/XHV83,2."0,L$ZF0XQW_+$@KPR3\.
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M;EDA7A07.=T#)CN]\-<S_:4K?E?]S0WPL7KWC0^PE"?63(8))SYT_,;4:<0
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M'LT#N,$DR4!/@:9Y_<;KDO/]W2^+/+N)PRA\R*7S.S8GU]EM=/.P*16V'L$
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M7ALS;;*\TG8GAS]+J^6M:\&-5]XTF)#E0W8K5O<DV/B(CU*=K*HR4BL98M4
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M]3HL6;78A#.AF;#U-+@P(-4@TM<P']U'E7@O<2]=&_9G\<XYHEQ/%RD$X75
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MQ$A7!C6;ONL&2HBC$IZ1\\C.[_HN!<]Y )T'V'_. SP 36!7S(4&M\#*\W'
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MU3;/6J.KZZD_A,4V/,ZR+]4&%SRIAH>Z82XK4]DP6=*9CYOND8HS[.D2= M
M"F&^"Y/&L<WJ/N6 MF0KR!BH4&.[@XD+:S',(6R9G?8DJHYJOJ"]?K#K+7;F
M.]X6BKK/&9RI(P*.@/BC'CIDDA',G2.="E9K$1XV95\?Y-6HUBBDMH)!J>C_
M V>H\&PKM7OW*;#NX4NPE')K$9+#.D\P) GVA. ;J$2@.B)7.\.=^TM-; ^
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M4!L  &=O<W,M,C R,S W,3DN>'-D4$L! A0#%     @ (8#T5K,#'4Y."@
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=>#0Q+FAT;5!+!08     !P ' -@!   0.@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
